Supporting Information

Asymmetric catalytic Friedel–Crafts alkylation with arenes and

heteroarenes: construction of 3,3-disubstituted oxindoles

Tinghui Zhang¹, Ziwei Zhong¹, Zi Zeng¹, Zitong Zhu¹, Fei Wang², YuXin Zhang², Xiaohua Liu¹, Maoping Pu^{1*} and Xiaoming Feng^{1*}

¹Key Laboratory of Green Chemistry & Technology, Ministry of Education, College of Chemistry, Sichuan University, Chengdu 610064, China

²Center for Natural Products Research, Chengdu Institute of Biology, Chinese Academy of Sciences, Chengdu 610064, China

E-mail: xmfeng@scu.edu.cn; pump@scu.edu.cn

Content

1 General Information	3
2 Typical procedure for preparation of products	4
3 Optimization of the reaction conditions	5
4 Gram-scale synthesis of C1	13
5 Synthetic transformations	14
6 Control experiments	14
7 Comparison of nucleophilicity parameters for arenes and heteroarenes	15
8 Unsuccessful substrate scopes	15
9 Bioactivity Study	15
10 Determination of absolute configuration of products	21
11 Characterization of the products	27
12 Copies of NMR spectra for products	97
13 Reference	169

1 General Information

NMR characterization data were collected on bruker ASCEND[™] operating at 400 MHz for ¹H NMR, 101 MHz for ¹³C NMR (with complete proton decoupling), and 376 MHz for ¹⁹F NMR (with complete proton decoupling). ¹H NMR and ¹³C NMR: chemical shifts δ were recorded in ppm relative to tetramethylsilane and internally referenced to the residual solvent signal (for ¹H NMR, CDCl₃: δ = 7.26 ppm, acetone- d_6 : δ =2.05 ppm; for ¹³C NMR: CDCl3: δ = 77.0 ppm, acetone-d6: δ = 29.8 ppm, 206.1 ppm). Data were reported as follows: chemical shift, multiplicity (s = singlet, d = doublet, t = triplet, q = quartet, dd = doublet of doublets, m = multiplet), coupling constants (Hz), integration. Ultra Performance Convergence Chromatography (UPC²) was performed on using Daicel Chiralcel IB-3, AS-3, ID-3, OD-3 at 23 °C with UV detector at 254 nm, and enantiomeric excesses were determined in comparison with the authentic racemates. High resolution mass spectra (HRMS) were performed on Thermo Q-Exactive Focus (FTMS+c ESI) and data were reported as (m/z). Infrared spectra (IR) were recorded on Bruker Tensor II spectrometer with Plantium ATR accessory and the peaks are reported as absorption maxima (v, cm⁻¹). Optical rotations were measured on Rudolph Research Analytic Automatic Polarimeter, and reported as follows: $[\alpha]_D^T$ (c: g/100 mL, in CH₂Cl₂). Melting point ranges were determined on OptiMelt. X-ray crystallographic data were collected by a Bruker D8 Venture Photon II. The experiments requiring substrates 3-Bromo-3-substituted oxindoles¹ and chiral N,N⁻dioxide ligands² were synthesized according to known procedures and purified by recrystallization prior to use. All of the starting materials including the metal salts were purchased from TCI, Aladdin, Adamas, Acros, Aldrich and other companies, and used without further purification. The 3/4/5Å MS and inorganic base was purchased from Acros and oven-dried by the muffle furnace for 4 h prior to use. All the solvents were pre-dried over appropriate desiccants, and distilled prior to use. other commercial reagents were used without further purification. Reactions were monitored using thin-layer chromatography (TLC) on GF254 silica gel. Visualization of the developed plates was performed under UV light (254 nm) or using iodine, cobalt thiocyanate or KMnO₄. The products were purified by flash column chromatography with silicycle 300-400 mesh silica gel.

2 Typical procedure for preparation of products

The corresponding racemic products were obtained by using racemic N,N-dioxide (±)-L₂-**PiPr**₂ as the ligand under the respective catalytic reaction conditions.

2.1 Typical procedure for preparation of products (condition A)



An oven-dried test tube was charged with metal salt Ni(OTf)₂ (3.6 mg, 0.01 mmol, 10 mol %), L_2 -PiPr₂ (6.3 mg, 0.01 mmol, 10 mol %) 3-Bromo-3-substituted oxindoles A1 (0.10 mmol), K_2CO_3 (16.6 mg, 0.12 mmol, 1.2 equiv.) under N₂ atmosphere. Anhydrous DCE (1.0 mL) was added and the mixture was stirred at 35 °C for 30 minutes. Subsequently, the arenes B1 (0.15 mmol 1.5 equiv.) were added and the reaction was performed at 0 °C for 24 hours. The reaction mixture was directly subjected to flash column chromatography on silica gel (eluent: petroleum ether/ethyl acetate = 3:1 to 1:1) to afford the corresponding products C1

2.2 Typical procedure for preparation of products (condition B)



An oven-dried test tube was charged with metal salt Ni(acac)₂ (1.3 mg, 0.005 mmol, 5 mol %), L_2 -PiEt₂ (3.5 mg, 0.006 mmol, 6 mol %) 3-Bromo-3-substituted oxindoles A1 (22.6 mg, 0.10 mmol, 1 equiv.), 4 Å molecular sieves (30 mg) under N₂ atmosphere. Anhydrous DCE (1.0 mL) was added and the mixture was stirred at 35 °C for 30 minutes. Subsequently, the arenes B23 (0.12 mmol 1.2 equiv.), *i*Pr₂NEt (16.5 mg, 0.10 mmol, 1.0 equiv.) was added at 0 °C and the reaction was performed at 0 °C for 12 hours. The reaction mixture was directly subjected to flash column chromatography on silica gel (eluent: petroleum ether/ethyl acetate = 4:1 to 2:1) to afford the corresponding products C27.

2.3 Typical procedure for preparation of products (condition C)



An oven-dried test tube was charged with metal salt Ni(OTf)₂ (3.6 mg, 0.01 mmol, 10 mol %), L_3 -PiEt₂Me (6.2 mg, 0.01 mmol, 10 mol %) 3-Bromo-3-substituted oxindoles A8 (0.10 mmol), K₂CO₃ (16.6 mg, 0.12 mmol, 1.2 equiv.) under N₂ atmosphere. Anhydrous DCE (1.0 mL) was added and the mixture was stirred at 35 °C for 30 minutes. Subsequently, the arenes B1 (20.7 mg, 0.15 mmol 1.5 equiv.) were added and the reaction was performed at 0 °C for 24 hours. The reaction mixture was directly subjected to flash column chromatography on silica gel (eluent: petroleum ether/ethyl acetate = 3:1 to 1:1) to afford the corresponding products C54.

3 Optimization of the reaction conditions

3.1 Optimization of the reaction conditions (condition A)

Table S1. Screening of metal salts



entry ^a	metal salts	yield (%) ^b	ee (%) ^c
1	Mg(OTf) ₂	34	20
2	Sc(OTf) ₃	41	11
3	Fe(OTf) ₂	52	25
4	Co(OTf) ₂	35	37
5	Ni(OTf) ₂	60	85
6	Cu(OTf) ₂	53	38
7	Zn(OTf) ₂	44	67
8	Y(OTf) ₃	10	0
9	La(OTf) ₃	trace	0
10	Dy(OTf) ₃	trace	0
11	NiCl ₂	trace	0
12	Ni(BF ₄) ₂ .6H ₂ O	21	35
13	Ni(ClO ₄) ₂ ·6H ₂ O	33	18
14	Ni(acac) ₂	78	68
15 ^d	Ni(OTf) ₂	62	80
16 ^e	Ni(OTf) ₂	66	88
17 ^f	Ni(OTf) ₂	53	89
18 ^g	Ni(OTf) ₂	60	88
19 ^{<i>h</i>}	Ni(OTf) ₂	66	88
20 ^{<i>i</i>}	Ni(OTf) ₂	9	39

^aThe reactions were performed with A1 (0.10 mmol), B1 (0.15 mmol), K₂CO₃ (0.12 mmol) and metal salt/L₃-PiEt₂Me (1:1, 10 mol %)

in DCE (1.0 mL) at 20 °C for 24 h. ^bYield of the isolated product. ^cDetermined by UPC² analysis on a chiral stationary phase. ^dThe reaction was performed at 10 °C. ^eThe reaction was performed at 0 °C. ^fThe reaction was performed at -10 °C ^g0.12 mmol **B1** was added. ^h0.20 mmol **B1** was added. ⁱ4 Å molecular sieves (20.0 mg) was added.

Table S2. Screening of ligands





 $\begin{array}{l} \textbf{L_3-PrMe_2: R = 2,6-Me_2C_6H_3 m = 1} \\ \textbf{L_3-PrEt_2Me: R = 2,6-Et_2-MeC_6H_2 m = 1} \end{array}$



 L_2 -PiPr₂: R = 2,6-*i*Pr₂C₆H₃ m = 0



R H - H R **L₃-RaMe₂:** R = 2,6-Me₂C₆H₃ m = 1 **L₃-RaEt₂Me**: R = 2,6-Et₂-MeC₆H₂ m = 1

entry^a Ligands yield (%)^b ee (%)^c 1 L₃-PrMe₂ 41 64 2 L₃-PrEt₂Me 73 45 3 L₃-RaMe₂ 76 35 L₃-RaEt₂Me 71 40 4 5 L₃-PiMe₂ 58 74 6 L₃-PiEt₂ 70 90 7 L₃-PiEt₂Me 66 88 8 L₃-PiPr₂ 86 84 9 L₄-PiPr₂ 77 54 L₂-PiMe₂ 78 91 10 L₂-PiEt₂ 61 93 11 12 L₂-PiPr₂ 80 94

^aThe reactions were performed with A1 (0.10 mmol), B1 (0.15 mmol), K_2CO_3 (0.12 mmol) and Ni(OTf)₂/Ligand (1:1, 10 mol %) in DCE (1.0 mL) at 0 °C for 24 h. ^bYield of the isolated product. ^cDetermined by UPC² analysis on a chiral stationary phase.

Table S3. Screening of base



entry ^a	base	yield (%) ^b	ee (%) ^c
1	Na ₂ CO ₃	27	77
2	K ₂ CO ₃	80	94
3	Cs ₂ CO ₃	26	34
4	Et ₃ N	N.D.	-
5	Pr ₃ N	N.D.	-
6	DMAP	N.D.	-

^aThe reactions were performed with **A1** (0.10 mmol), **B1** (0.15 mmol), base (0.12 mmol) and Ni(OTf)₂/L₂-**PiPr**₂ (1:1, 10 mol %) in DCE (1.0 mL) at 0 °C for 24 h. ^bYield of the isolated product. ^cDetermined by UPC² analysis on a chiral stationary phase.

Table S4. Solvent Screening.



entry ^a	solvent	yield (%) ^b	ee (%) ^c
1	CH_2CI_2	78	94
2	CHCl₃	75	86
3	DCE	80	94
4	THF	trace	14
5	Et ₂ O	N.R.	-
6	toluene	N.R.	-

^aThe reactions were performed with **A1** (0.10 mmol), **B1** (0.15 mmol), K₂CO₃ (0.12 mmol) and Ni(OTf)₂/**L**₂-**PiPr**₂ (1:1, 10 mol %) in solvent (1.0 mL) at 0 °C for 24 h. ^bYield of the isolated product. ^cDetermined by UPC² analysis on a chiral stationary phase.

Table S5. Screening of the amount of base



entry ^a	the amount of K_2CO_3 (x mmol)	yield (%) ^b	ee (%) ^c
1	0.10	78	91
2	0.12	81	94
3	0.15	81	91
4	0.20	80	89
5	0.30	79	86

^aThe reactions were performed with **A1** (0.10 mmol), **B1** (0.15 mmol), K₂CO₃ (x mmol) and Ni(OTf)₂/L₂-**PiPr**₂ (1:1, 10 mol %) in DCE (1.0 mL) at 0 °C for 24 h. ^bYield of the isolated product. ^cDetermined by UPC² analysis on a chiral stationary phase.

3.2 Optimization of the reaction conditions (condition B)

 Table S6.
 Screening of metal salts.



entry ^a	metal salts	yield (%) ^b	ee (%) ^c
1	Mg(OTf) ₂	92	0
2	Sc(OTf) ₃	98	0
3	Fe(OTf) ₂	95	0
4	Co(OTf) ₂	91	12
5	Ni(OTf) ₂	96	51
6	Cu(OTf) ₂	95	23
7	Zn(OTf) ₂	92	0
8	Y(OTf) ₃	90	0
9	La(OTf) ₃	99	0
10	Tb(OTf) ₃	94	0
11 ^{<i>d</i>}	Ni(OTf) ₂	96	43
12 ^e	Ni(OTf) ₂	96	51
13 ^f	Ni(OTf) ₂	55	51
14 ^{<i>g</i>}	Ni(OTf) ₂	25	43

^eThe reactions were performed with **A1** (0.10 mmol), **B12** (0.12 mmol), K_2CO_3 (0.12 mmol) and metal salt/L₃-**PiEt₂Me** (1:1, 10 mol %) in DCE (1.0 mL) at 0 °C for 12 h. ^bYield of the isolated product. ^oDetermined by UPC² analysis on a chiral stationary phase. ^oThe reaction was performed at 10 °C. ^eThe reaction was performed at 0 °C. ^fThe reaction was performed at -10 °C ^g0.12 mmol **B1** was added. ^oThe reaction was performed at 10 °C. ^eThe reaction was performed at -30 °C ^gThe reaction was performed at -30 °C

Table S7. Screening of ligands.



łm.



L₃-PiEt₂: R = 2,6-Et₂C₆H₃ m = 1 L₃-PiEt₂Me: R = 2,6-Et₂-4-MeC₆H₂ m = 1 L₃-PiEt₂Br: R = 2,6-Et₂-4-BrC₆H₂ m = 1 L_3 -PiPr₂: R = 2,6-*i*Pr₂ C_6H_3 m = 1 L_4 -PiPr₂: R = 2,6-*i*Pr₂C₆H₃ m = 2 L_2 -PiMe₂: R = 2,6-Me₂C₆H₃ m = 0 L_2 -**PiEt**₂: R = 2,6-Et₂ C_6 H₃ m = 0 L_2 -PiPr₂: R = 2,6-*i*Pr₂C₆H₃ m = 0



L₃-RaMe₂: R = 2,6-Me₂C₆H₃ m = 1 **L₃-RaEt₂Me**: R = 2,6-Et₂-MeC₆H₂ m = 1

entry ^a	Ligands	yield (%) ^b	ee (%) ^c
1	L ₃ -PrMe ₂	91	33
2	L₃-PrEt₂Me	92	43
3	L ₃ -RaMe ₂	96	10
4	L₃-RaEt₂Me	95	47
5	L ₃ -PiMe ₂	97	53
6	L ₃ -PiMe ₃	92	58
7	L ₃ -PiEt ₂	66	54
8	L ₃ -PiEt ₂ Me	83	51
9	L ₃ -PiEt ₂ Br	90	20
10	L ₃ -PiPr ₂	98	49
11	L ₄ -PiPr ₂	97	29
12	L ₂ -PiPr ₂	95	55
13	L ₂ -PiMe ₂	90	41
14	L ₂ -PiEt ₂	92	59

"The reactions were performed with A1 (0.10 mmol), B12 (0.12 mmol), K2CO3 (0.12 mmol) and Ni(OTf)2/Ligand (1:1, 10 mol %) in DCE (1.0 mL) at 0 °C for 24 h. ^bYield of the isolated product. ^cDetermined by UPC² analysis on a chiral stationary phase.

Table S8. Screening of Counterion of Ni(II) salts.



entry ^a	NiX ₂	yield (%) ^b	ee (%) ^c
1	NiCl ₂	95	0
2	NiBr ₂	95	0
3	Ni(acac) ₂	91	80

4	Ni(OTf) ₂	92	59
5	Ni(BF ₄) ₂ .6H ₂ O	99	30
6	Ni(ClO ₄) ₂ .6H ₂ O	96	28
7	NiC ₂ O ₄ ·6H ₂ O	92	0

^aThe reactions were performed with **A1** (0.10 mmol), **B12** (0.12 mmol), K₂CO₃ (0.12 mmol) and NiX₂/L₂-**PiEt**₂ (1:1, 10 mol %) in DCE (1.0 mL) at 0 °C for 12 h. ^bYield of the isolated product. ^cDetermined by UPC² analysis on a chiral stationary phase.

Table S9. Solvent Screening.



^aThe reactions were performed with A1 (0.10 mmol), B12 (0.12 mmol), K₂CO₃ (0.12 mmol) and Ni(acac)₂/L₂-PiEt₂ (1:1, 10 mol %) in solvent (1.0 mL) at 0 °C for 12 h. ^bYield of the isolated product. ^cDetermined by UPC² analysis on a chiral stationary phase.

Table S10. Screening of base



entry ^a	base	yield (%) ^b	ee (%) ^c
1	Na ₂ CO ₃	89	36
2	K ₂ CO ₃	91	80
3	Cs ₂ CO ₃	90	60
4	Et ₃ N	87	86
5	Pr ₃ N	85	84
6	<i>i</i> Pr ₂ NEt	86	90
7	DMAP	complex	-

^aThe reactions were performed with **A1** (0.10 mmol), **B1** (0.12mmol), base (0.12 mmol) and Ni(acac)₂/L₂-**PiEt**₂ (1:1, 10 mol %) in DCE (1.0 mL) at 0 °C for 12 h. ^bYield of the isolated product. ^cDetermined by UPC² analysis on a chiral stationary phase.



entry ^a	the amount of <i>i</i> Pr ₂ NEt (x mmol)	yield (%) ^b	ee (%) ^c
1	0.10	90	90
2	0.12	86	90
3	0.15	82	88
4	0.20	76	82

^aThe reactions were performed with **A1** (0.10 mmol), **B12** (0.12 mmol), *i*Pr₂NEt (x mmol) and Ni(acac)₂/L₂-**PiEt**₂ (1:1, 10 mol %) in DCE (1.0 mL) at 0 °C for 12 h. ^bYield of the isolated product. ^cDetermined by UPC² analysis on a chiral stationary phase.

Table S12. Screening of the amount of catalyst



١

entry ^a	the amount of catalyst (x mmol %)	yield (%) ^b	ee (%) ^c
1	10	90	90
2	5	90	87
3	2	72	88

^aThe reactions were performed with A1 (0.10 mmol), B12 (0.12 mmol), *i*Pr₂NEt (0.12 mmol) and Ni(acac)₂/L₂-PiEt₂ (1:1, x mol %) in DCE (1.0 mL) at 0 °C for 12 h. ^bYield of the isolated product. ^cDetermined by UPC² analysis on a chiral stationary phase.

Table S13. Screening of the ratio of Ni(acac)₂ and L₂-PiEt₂

	Br NH H A1	Ni(acac) ₂ /L ₂ -PiEt ₂ (1:x, 5 mol %) /Pr ₂ NEt (1.0 equiv.) DCE, 0 °C B27		
entry ^a	x	yield (%) ^b	ee (%) ^c	
1	0.8	91	81	
2	1.0	90	87	
3	1.2	90	91	
3	1.6	85	91	

^aThe reactions were performed with **A1** (0.10 mmol), **B12** (0.12 mmol), *i*Pr₂NEt (0.10 mmol) Ni(acac)₂ (0.005 mmol) and L₂-PiEt₂ (0.005y mmol) in DCE (1.0 mL) at 0 °C for 12 h. ^bYield of the isolated product. ^cDetermined by UPC² analysis on a chiral stationary phase.



^aThe reactions were performed with A1 (0.10 mmol), B12 (0.12 mmol), *i*Pr₂NEt (0.10 mmol), Ni(acac)₂ (0.005 mmol), L₂-PiEt₂ (0.006 mmol) and additive in DCE (1.0 mL) at 0 °C for 12 h. ^bYield of the isolated product. ^cDetermined by UPC² analysis on a chiral stationary phase.

3.3 Optimization of the reaction conditions (condition C)

Table S15. Screening of metal salts.



entry ^a	metal salts	yield (%) ^b	ee (%) ^c
1	Mg(OTf) ₂	68	20
2	Sc(OTf) ₃	34	0
3	Fe(OTf) ₂	62	35
4	Co(OTf) ₂	88	17
5	Ni(OTf) ₂	89	70
6	Cu(OTf) ₂	68	28

^aThe reactions were performed with **A8**(0.10 mmol), **B1** (0.15 mmol), K₂CO₃ (0.12 mmol) and metal salt/L₂-**PiPr**₂ (1:1, 10 mol %) in DCE (1.0 mL) at 0 °C for 24 h. ^bYield of the isolated product. ^cDetermined by UPC² analysis on a chiral stationary phase.

Table S16. Screening of ligands.









 L_3 -PrEt₂Me: R = 2,6-Et₂-MeC₆H₂ m = 1

 $\begin{array}{l} \textbf{L_3-PiMe_2: } R = 2,6-Me_2C_6H_3\ m = 1\\ \textbf{L_3-PiEt_2: } R = 2,6-Et_2C_6H_3\ m = 1\\ \textbf{L_3-PiEt_2Me: } R = 2,6-Et_2-4-MeC_6H_2\ m = 1\\ \textbf{L_3-PiPr_2: } R = 2,6-iPr_2C_6H_3\ m = 1\\ \textbf{L_2-PiMe_2: } R = 2,6-Me_2C_6H_3\ m = 0\\ \textbf{L_2-PiEt_2: } R = 2,6-Et_2C_6H_3\ m = 0\\ \textbf{L_2-PiEt_2: } R = 2,6-iPr_2C_6H_3\ m = 0\\ \textbf{L_2-PiEt_2: } R = 2,6-iPr_2C_6H_3\ m = 0\\ \end{array}$

L₃-RaEt₂Me: R = 2,6-Et₂-MeC₆H₂ m = 1

entry ^a	Ligands	yield (%) ^b	ee (%) ^c
1	L ₂ -PiMe ₂	91	50
2	.L ₂ -PiEt ₂	76	91
3	L ₂ -PiPr ₂	89	70
4 ^{<i>d</i>}	L ₂ -PiPr ₂	N.D.	-
5	L ₃ -PiMe ₂	58	52
6	L ₃ -PiEt ₂	89	90
7	L ₃ -PiEt ₂ Me	93	93
8	L ₃ -PiPr ₂	78	83
9	L ₃ -PrEt ₂ Me	91	85
10	L ₃ -RaEt ₂ Me	88	47

^aThe reactions were performed with **A1** (0.10 mmol), **B12** (0.15mmol), K_2CO_3 (0.12 mmol) and Ni(OTf)₂/Ligand (1:1, 10 mol %) in DCE (1.0 mL) at 0 °C for 24 h. ^bYield of the isolated product. ^cDetermined by UPC² analysis on a chiral stationary phase. ^d_iPr₂NEt instead of K₂CO₃

4 Gram-scale synthesis of C1



An oven-dried test tube was charged with metal salt Ni(OTf)₂ (3.6 mg, 0.5 mmol, 10 mol %), L_2 -PiPr₂ (6.3 mg, 0.5 mmol, 10 mol %) 3-Bromo-3-substituted oxindoles A1 (5.0 mmol), K₂CO₃ (16.6 mg, 6.0 mmol, 1.2 equiv.) under N₂ atmosphere. Anhydrous DCE (15 mL) was added and the mixture was stirred at 35 °C for 30 minutes. Subsequently, the arenes B1 (1.0 mL 1.5 equiv.) was added and the reaction was performed at 0 °C for 24 hours. The reaction mixture was filtered (solvent: DCM), and concentrated under reduced pressure, the crude product was subjected to flash column chromatography on silica gel and eluted with petroleum ether/ethyl acetate (6/1 to 1/1) to afford the corresponding product C1 (1.06 g, 75% yield, 94% ee).

5 Synthetic transformations

5.1 Procedure for the synthesis of D1



Compound **C40**: An oven-dried test tube was charged with metal salt Ni(OTf)₂ (7.2 mg, 0.02 mmol, 10 mol %), **L₃-PiEt₂Me** (12.4 mg, 0.02 mmol, 10 mol %) 3-Bromo-3-substituted oxindoles **A16** (56.8 mg, 0.20 mmol, 1.0 equiv.), K₂CO₃ (33.2 mg, 0.24 mmol, 1.2 equiv.) under N₂ atmosphere. Anhydrous DCE (2.0 mL) was added and the mixture was stirred at 35 °C for 30 minutes. Subsequently, the arenes **B1** (41.2 μ L, 0.30 mmol 1.5 equiv.) was added and the reaction was performed at 0 °C for 24 hours. The reaction mixture was directly subjected to flash column chromatography on silica gel (eluent: petroleum ether/ethyl acetate = 4/1 to 2/1, v/v) to afford the corresponding product **C40** (45.1 mg, 66% yield, 97% ee).

Compound **D1**: An oven-dried test tube was charged with **C40** (43.1 mg, 0.13 mmol, 1.0 equiv.) and Cs₂CO₃ (84.7 mg, 0.26 mmol, 2.0 equiv.) and iodomethane (39.9 μ L, 0.65 mmol, 5.0 equiv.). Anhydrous THF (1.0 mL) was added and the mixture was stirred at room temperature for 12 hours. Then the mixture was filtered and concentrated under reduced pressure. The residue was dissolved in dry THF under N₂ atmosphere. Anhydrous THF (1.0 mL) was added, the LiAlH₄ (1 M in THF, 0.39 mL, 0.39 mmol, 3.0 equiv.) was added in 0 °C and the mixture was stirred at 0 °C for 4 hours and then treated with several drops of NaSO₄·10H₂O until the evolution of H₂ ceased. The reaction mixture was directly subjected to flash column chromatography on silica gel (eluent: petroleum ether/ethyl acetate = 19/1 to 9/1, v/v) to afford the corresponding product **D2** (35.9 mg, 87% yield, 97% ee). in 95% yield with 97% ee.

5.2 Procedure for the synthesis of D2



Compound **C1**: An oven-dried test tube was charged with metal salt Ni(OTf)₂ (7.2 mg, 0.02 mmol, 10 mol %), **L₂-PiPr**₂ (12.6 mg, 0.02 mmol, 10 mol %) 3-Bromo-3-substituted oxindoles **A1** (45.2 mg, 0.20 mmol, 1.0 equiv.), K₂CO₃ (33.2 mg, 0.24 mmol, 1.2 equiv.) under N₂ atmosphere. Anhydrous DCE (2.0 mL) was added and the mixture was stirred at 35 °C for 30 minutes. Subsequently, the arenes **B1** (39.0 μ L, 0.30 mmol 1.5 equiv.) was added and the reaction was performed at 0 °C for 24 hours. The reaction mixture was directly subjected to flash column chromatography on silica gel (eluent: petroleum ether/ethyl acetate = 3/1 to 1/1, v/v) to afford the corresponding product **C1** (46.1 mg, 80% yield, 94% ee).

Compound **D2**: An oven-dried test tube was charged with **C1** (28.8 mg, 0.10 mmol, 1.0 equiv.) and BBr₃ (1 M in DCM, 0.30 mL, 0.30 mmol, 3.0 equiv.). Anhydrous DCM (1.0 mL) was added and the mixture was stirred at room temperature for 12 hours. Then 0.2 mL

water was added in 0 °C to quench the reaction. The reaction mixture was directly subjected to flash column chromatography on silica gel (eluent: petroleum ether/ethyl acetate = 2/1 to 1/2, v/v) to afford the corresponding product **D2** (23.2 mg, 91% yield, 94% ee).

5.3 Procedure for the synthesis of D4



Compound **C40**: An oven-dried test tube was charged with metal salt $Zn(OTf)_2$ (10.8 mg, 0.03 mmol, 20 mol %), **L**₃-**PiPr**₂ (18.0 mg, 0.03 mmol, 20 mol %), NaBAr ^F₄ (13.3 mg, 0.015 mmol, 10 mol%) 3-Bromo-3-substituted oxindoles **A1** (33.9 mg, 0.15 mmol, 1.0 equiv.), K₂CO₃ (24.9 mg, 0.18 mmol, 1.2 equiv.) under N₂ atmosphere. Anhydrous DCE (1.5 mL) was added and the mixture was stirred at 35 °C for 30 minutes. Subsequently, the arenes **B1** (57.3 µL, 0.30 mmol 3.0 equiv.) was added and the reaction was performed at 10 °C for 24 hours. The reaction mixture was directly subjected to flash column chromatography on silica gel (eluent: petroleum ether/ethyl acetate = 4/1 to 2/1, v/v) to afford the corresponding product **C18** (34.2 mg, 79% yield, 76% ee).

Compound **D3**: An oven-dried test tube was charged with **C18** (22.8 mg, 0.079 mmol, 1.0 equiv.) and NaH (3.8 mg, 0.158 mmol, 2.0 equiv.) and iodomethane (19.6 μ L, 0.158 mmol, 2.0 equiv.). Anhydrous DMF (1.0 mL) was added and the mixture was stirred at room temperature for 12 hours. Then the reaction mixture was directly subjected to flash column chromatography on silica gel (eluent: petroleum ether/ethyl acetate = 9/1 to 4/1, v/v) to afford the corresponding product **D3** (25.6 mg, 92% yield, 76% ee).

Compound **D4**: An oven-dried test tube was charged with **D3** (25.6 mg, 0.073 mmol, 1.0 equiv.) and BBr₃ (1 M in DCM, 0.22 mL, 0.22 mmol, 3.0 equiv.). Anhydrous DCM (1.0 mL) was added and the mixture was stirred at room temperature for 12 hours. Then 0.2 mL water was added in 0 °C to quench the reaction. The resulting mixture was extracted with DCM. The organic layer was washed with brine, dried over anhydrous Na₂SO4, filtered and concentrated under reduced pressure. The crude product is directly used for the next step. An oven-dried test tube was charged with crude product, Cs_2CO_3 (71.7 mg, 0.22 mmol, 3.0 equiv.) and CH_2I_2 (17.7 µL, 0.22 mmol, 3.0 equiv.). Anhydrous DMF (1.0 mL) was added and the mixture was stirred at 80 °C for 12 hours. The reaction mixture was directly subjected to flash column chromatography on silica gel (eluent: petroleum ether/ethyl acetate = 19/1 to 9/1, v/v) to afford the corresponding product **C4** (18.5 mg, 75% yield, 76% ee).

6 Control experiments



An oven-dried test tube was charged with corresponding catalyst, K_2CO_3 (0.12 mmol, 1.2 equiv.) 3-Bromo-3-substituted oxindoles **A1** (0.10 mmol, 1 equiv.), under N₂ atmosphere. Anhydrous DCE (1.0 mL) was added and the mixture was stirred at 35 °C for 30 minutes. Subsequently, the arenes **B1** (0.30 mmol 3.0 equiv.), *i*Pr₂NEt (0.10 mmol, 1.0 equiv.) was added at 0 °C and the reaction was performed at 0 °C for 12 hours. The reaction mixture was directly subjected to flash column chromatography on silica gel (eluent: petroleum ether/ethyl acetate = 3:1 to 1:1) to afford the corresponding products **C1**.

An oven-dried test tube was charged with corresponding catalyst, 3-Bromo-3-substituted oxindoles **A1** (0.10 mmol, 1 equiv.), under N₂ atmosphere. Anhydrous DCE (1.0 mL) was added and the mixture was stirred at 35 °C for 30 minutes. Subsequently, the arenes **B23** (0.30 mmol 3.0 equiv.), *i*Pr₂NEt (0.10 mmol, 1.0 equiv.) was added at 20 °C and the reaction was performed at 20 °C for 12 hours. The reaction mixture was directly subjected to flash column chromatography on silica gel (eluent: petroleum ether/ethyl acetate = 4:1 to 2:1) to afford the corresponding products **C23**.

7 Comparison of nucleophilicity parameters for arenes and heteroarenes



The nucleophilicity of arenes and heteroarenes derived from Mayr's Database.

8 Unsuccessful substrate scopes



9 Bioactivity Study

Cell Culture

Hepatocellular carcinoma cell line HCCLM3 (obtained from Procell) were cultured with DMEM (Hyclone, Utah) supplemented with 10 % (v/v) FBS (Gibco, New York), 1 % (v/v) penicillin/streptomycin (Beyotime, Shanghai). All cells were cultured in incubator with 5% CO₂ at 37 °C.

Cell Viability Assay

Cells of logarithmic growth stage were inoculated in 96-well plate with density of 1.5*104 per well. Overnight all cells which density at 80 %, were treated with 1 % DMSO (negative control) and other compounds with different concentrations at 37 °C for 24h. No FBS DMEM with 10 % (v/v) CCK-8 (Selleck, Houston) was added to each well and incubated for 1h at 37 °C. The absorbance was determined at 450 nm to calculated cell viability (%). IC₅₀ was detected using Graphpad Prism. Each experiment was repeated three times.

Synthetic compounds inhibit hepatocellular carcinoma viability screening

To study the anti-hepatocellular carcinoma (HCCLM3) of synthetic compounds. We measured the HCCLM3 cell viability after exposed to each compound with 25 μ M for 24h. The results showed that **C38** and **C55** had strong inhibitory effect on the proliferation and viability of HCCLM3 and the IC₅₀ concentrations of **C38** and **C55** treated HCCLM3 cells for 24 h are 11.63 μ M and 11.16 μ M respectively.







10 Determination of absolute configuration of products

10.1 Determination of absolute configuration of compound C27

Crystals suitable for the X-ray crystal structure analysis were obtained from a solution of compound **C27** in ethyl acetate (ca. 0.1 mL) and petroleum ether (0.3 mL) at r.t.. The colourless crystal in block-shape, with approximate dimensions of 0.234 × 0.287 × 0.376 mm³, was selected and mounted for the single-crystal X-ray diffraction. The data set was collected by Bruker D8 Venture Photon II diffractometer at 173(2) K equipped with micro-focus Cu radiation source ($K_{\alpha} = 1.54178$ Å). Applied with face-indexed numerical absorption correction, the structure solution was solved and refinement was processed by SHELXTL (version 6.14) and OLEX 2.3 program package³. The structure was analyzed by ADDSYM routine implemented in PLATON suite and no higher symmetry was suggested⁴.





Crystallographic Data for $C_{17}H_{18}N_2O$

Formula	C ₁₇ H ₁₈ N ₂ O
Formula mass (amu)	266.33
Space group	P212121
<i>a</i> (Å)	6.4469 (2)
<i>b</i> (Å)	9.2442 (3)
<i>c</i> (Å)	24.0016 (7)
α (deg)	90
β (deg)	90
γ (deg)	90
$V(\text{\AA}^3)$	1430.41 (8)
Ζ	4
λ (Å)	1.54178
<i>T</i> (K)	173
ρ_{calcd} (g cm ⁻³)	1.237
$\mu (\mathrm{mm}^{-1})$	0.612
Transmission factors	0.859–0.933
$2\theta_{\max}(\text{deg})$	68.228
No. of unique data, including $F_0^2 < 0$	2611
No. of unique data, with $F_0^2 > 2\sigma(F_0^2)$	2593
No. of variables	189
$R(F)$ for $F_{o}^{2} > 2\sigma(F_{o}^{2})^{a}$	0.0237
$R_{\rm w}(F_{\rm o}^2)^{b}$	0.0640
Goodness of fit	1.106

 $^{a} R(F) = \sum ||F_{o}| - |F_{c}|| / \sum |F_{o}|.$

^b $R_{\rm w}(F_{\rm o}^2) = \left[\sum [w(F_{\rm o}^2 - F_{\rm c}^2)^2] / \sum wF_{\rm o}^4\right]^{1/2}; w^{-1} = [\sigma^2(F_{\rm o}^2) + (Ap)^2 + Bp], \text{ where } p = \left[\max(F_{\rm o}^2, 0) + 2F_{\rm c}^2\right] / 3.$

10.2 Futher transformation of compound C23'



Compound **C23'**: An oven-dried test tube was charged with **C23** (18.0 mg, 0.071 mmol, 1.0 equiv.) and NaH (8.5 mg, 0.335 mmol, 5.0 equiv.) and BnBr (42.2 μ L, 0.335 mmol, 5.0 equiv.). Anhydrous THF (1.0 mL) was added and the mixture was stirred at room temperature for 12 hours. Then the reaction mixture was directly subjected to flash column chromatography on silica gel (eluent: petroleum ether/ethyl acetate = 9/1 to 4/1, v/v), the product was recrystallized with dichloromethane and petroleum ether to afford the corresponding product **C23'** (24.6 mg, 80% yield, 95% ee).

10.3 Determination of absolute configuration of compound C23'

Crystals suitable for the X-ray crystal structure analysis were obtained from a solution of compound **C23'** in dichloromethane (ca. 0.1 mL) and petroleum ether (0.3 mL) at r.t.. The colourless crystal in block-shape, with approximate dimensions of 0.216 × 0.219 × 0.266 mm³, was selected and mounted for the single-crystal X-ray diffraction. The data set was collected by Bruker D8 Venture Photon II diffractometer at 173(2) K equipped with micro-focus Cu radiation source ($K_{\alpha} = 1.54178$ Å). Applied with face-indexed numerical absorption correction, the structure solution was solved and refinement was processed by SHELXTL (version 6.14) and OLEX 2.3 program package³. The structure was analyzed by ADDSYM routine implemented in PLATON suite and no higher symmetry was suggested⁴.





Crystallographic Data for $C_{30}H_{27}NO_2$

Formula	C ₃₀ H ₂₇ NO ₂
Formula mass (amu)	433.52
Space group	P212121
a (Å)	9.7721(2)
<i>b</i> (Å)	12.5443(2)
c (Å)	19.4584(3)
α (deg)	90
β (deg)	90
γ (deg)	90
$V(Å^3)$	2385.41(7)
Ζ	4
λ(Å)	1.54178
<i>T</i> (K)	173
ρ_{calcd} (g cm ⁻³)	1.207
μ (mm ⁻¹)	0.586
Transmission factors	0.784–0.955
$2\theta_{\max}(\deg)$	68.312
No. of unique data, including $F_0^2 < 0$	4326
No. of unique data, with $F_0^2 > 2\sigma(F_0^2)$	4142
No. of variables	301
$R(F) \text{ for } F_{o}^{2} > 2\sigma(F_{o}^{2})^{a}$	0.0290
$R_{\rm w}(F_{ m o}{}^2)^{b}$	0.0705
Goodness of fit	1.038

 $^{a} R(F) = \sum ||F_{o}| - |F_{c}|| / \sum |F_{o}|.$

^b $R_{\rm w}(F_{\rm o}^2) = \left[\sum [w(F_{\rm o}^2 - F_{\rm c}^2)^2] / \sum wF_{\rm o}^4\right]^{1/2}; w^{-1} = [\sigma^2(F_{\rm o}^2) + (Ap)^2 + Bp], \text{ where } p = \left[\max(F_{\rm o}^2, 0) + 2F_{\rm c}^2\right] / 3.$

11 Characterization of the products

(S)-3-(2,4-dimethoxyphenyl)-3-methylindolin-2-one (C1)



White solid; 22.6 mg, 80% yield, 94% ee; melting point: 85–87 °C; $[\alpha]_D^{16.6} = -72.8$ (*c* = 0.12 in CH₂Cl₂). **UPCC** DAICEL CHIRALCEL AS-3, CO₂/MeOH = 90/10, flow rate = 1.5 mL/min, λ = 254 nm, t_R (major) = 4.67 min, t_R (minor) = 8.83 min.

¹**H NMR** (400 MHz, CDCl₃) δ 8.56 (s, 1H), 7.55 – 7.43 (d, *J* = 8.5 Hz 1H), 7.17 – 7.05 (m, 1H), 6.94 – 6.78 (m, 2H), 6.62 – 6.52 (dd, *J* = 8.5, 2.5 Hz, 1H), 6.38 – 6.33 (d, *J* = 2.5 Hz, 1H), 3.79 (s, 3H), 3.44 (s, 3H), 1.71 (s, 3H).

¹³**C NMR** (101 MHz, CDCl₃) δ 183.8, 160.7, 158.2, 140.7, 136.8, 128.3, 127.3, 122.5, 122.2, 122.0, 109.3, 104.6, 100.1, 55.7, 55.5, 50.1, 23.93.

IR: 2932, 1613, 1504, 1470, 1300, 1209, 1142, 1031, 756, 643 cm⁻¹.

HRMS (FTMS+c ESI) m/z: $[M + Na]^+$ calcd for $C_{17}H_{17}NO_3Na^+$ 306.1101; found 306.1103.



	Retention Time	Area	% Area
1	4.693	7334382	50.41
2	8.500	7215636	49.59



	Retention Time	Area	% Area
1	4.670	6829892	96.85
2	8.834	222370	3.15

(S)-3-(2,4-diethoxyphenyl)-3-methylindolin-2-one (C2)



White solid; 26.7 mg, 86% yield, 90% ee; melting point: 131–133 °C; $[\alpha]_D^{15.2} = -70.1$ (*c* = 0.24 in CH₂Cl₂).

UPCC DAICEL CHIRALCEL AS-3, CO₂/MeOH = 90/10, flow rate = 1.5 mL/min, λ = 254 nm, t_R (major) = 4.49 min, t_R (minor) = 6.77 min.

¹**H NMR** (400 MHz, CDCl₃) δ 8.93 (s, 1H), 7.53 – 7.40 (d, *J* = 8.6 Hz, 1H), 7.17 – 7.01 (m, 1H), 6.95 – 6.85 (m, 2H), 6.85 – 6.73 (m, 1H), 6.61 – 6.49 (dd, *J* = 8.5, 2.5 Hz, 1H), 6.37 – 6.28 (d, *J* = 2.5 Hz, 1H), 4.01 (q, *J* = 7.0 Hz, 2H), 3.78 (dq, *J* = 8.9, 7.0 Hz, 1H), 3.56 (dq, *J* = 8.9, 7.0 Hz, 1H), 1.71 (s,

3H), 1.39 (t, J = 7.0 Hz, 3H), 0.94 (t, J = 7.0 Hz, 3H).

¹³**C NMR** (101 MHz, CDCl₃) δ 184.1, 159.9, 157.3, 141.1, 137.1, 128.2, 127.2, 122.4, 122.1, 121.3, 109.4, 104.6, 100.3, 63.7, 63.6, 50.2, 23.8, 15.0, 13.8.

IR: 2977, 2926, 1613, 1583, 1263, 1188, 1141, 754, 650, 593 cm⁻¹.

HRMS (FTMS+c ESI) m/z: [M + Na]⁺ calcd for C₁₉H₂₁NO₃Na⁺ 334.1414; found 334.1414.



	Retention Time	Area	% Area
1	4.469	3749773	49.75
2	6.723	3787472	50.25



	Retention Time	Area	% Area
1	4.491	509538	5.23
2	6.769	9239624	94.77

(S)-3-(2,4-diisopropoxyphenyl)-3-methylindolin-2-one (C3)



White solid; 30.5 mg, 90% yield, 88% ee; melting point: 150–152 °C; $[\alpha]_D^{16.6} = -23.6$ (*c* = 0.31 in CH₂Cl₂).

UPCC DAICEL CHIRALCEL OX-3, CO₂/MeOH = 90/10, flow rate = 1.5 mL/min, λ = 254 nm, t_R (major) = 7.59 min, t_R (minor) = 12.45 min.

¹**H NMR** (400 MHz, CDCl₃) δ 8.66 (s, 1H), 7.56 – 7.30 (d, *J* = 8.6 Hz, 1H), 7.17 – 7.06 (m, 1H), 6.98 – 6.83 (m, 2H), 6.84 – 6.73 (m, 1H), 6.57 – 6.42 (dd, *J* = 8.6, 2.4 Hz, 1H), 6.35 – 6.24 (d, *J* = 2.4 Hz, 1H), 6.35 – 6.24 (d, J = 2.4 Hz, 1H), 6.35 – 6.24 (d, J = 2.4 Hz, 1H), 6.35 – 6.24 (d, J = 2.4 Hz, 1H), 6.35 – 6.24 (d, J = 2.4 Hz, 1H), 6.35 – 6.24 (d, J = 2.4 Hz, 1H), 6.35 – 6.24 (d, J = 2.4 Hz, 1H), 6.35 – 6.34 (d, J = 2.4 Hz, 1H), 6.35 – 6.24 (d, J = 2.4 Hz, 1H), 6.35 – 6.24 (d, J = 2.4 Hz, 1H), 6.35 – 6.24 (d, J = 2.4 Hz, 1H), 6.35 – 6.24 (d, J = 2.4 Hz, 1H), 6.35 – 6.24 (d, J = 2.4 Hz, 1H), 6.35 – 6.24 (d, J = 2.4 Hz, 1H), 6.35 – 6.24 (d, J = 2.4 Hz, 1H), 6.35 – 6.24 (d, J = 2.4 Hz, 1H), 6.35 – 6.24 (d, J = 2.4 Hz, 1H), 6.35 – 6.24 (d, J = 2.4 Hz, 1H), 6.35 – 6.34 (d, J = 2.4 Hz, 1H), 6.35 – 6.34 (d, J = 2.4 Hz, 1H), 6.35

1H), 4.59 – 4.40 (m, 1H), 4.36 – 4.23 (m, 1H), 1.69 (s, 3H), 1.32 (t, *J* = 6.4 Hz, 6H), 1.10 (d, *J* = 6.0 Hz, 3H), 0.59 (d, *J* = 6.0 Hz, 3H).

¹³**C NMR** (101 MHz, CDCl₃) *δ* 183.9, 158.8, 155.8, 141.2, 137.4, 128.4, 127.1, 122.5, 122.0, 121.6, 109.2, 105.4, 101.8, 70.0, 69.2, 50.2, 23.7, 22.4, 22.2, 21.4, 20.6.

IR: 2976, 1613, 1611, 1581, 1191, 1132, 1101, 952, 754, 652 cm⁻¹.

HRMS (FTMS+c ESI) m/z: [M + Na]⁺ calcd for C₂₁H₂₅NO₃Na⁺ 362.1727; found 362.1727.



	Retention Time	Area	% Area
1	7.631	5804403	50.74
2	12.346	5634463	49.26



	Retention Time	Area	% Area
1	7.592	5655425	93.96
2	12.447	363808	6.04

(S)-3-(2,4-dimethoxy-5-methylphenyl)-3-methylindolin-2-one (C4)



Colorless oil; 26.8 mg, 90% yield, 98% ee; $[\alpha]_D^{14.6} = -70.3$ (c = 0.16 in CH₂Cl₂). **UPCC** DAICEL CHIRALCEL AS-3, CO₂/MeOH = 90/10, flow rate = 1.5 mL/min, $\lambda = 254$ nm, t_R (major) = 4.34 min, t_R (minor) = 9.71 min. ¹H NMR (400 MHz, CDCl₃) δ 8.73 (s, 1H), 7.30 (s, 1H), 7.17 – 7.07 (m, 1H), 6.93 – 6.81 (m, 3H), 6.35

(s, 1H), 3.78 (s, 3H), 3.43 (s, 3H), 2.22 (s, 3H), 1.71 (s, 3H).

¹³C NMR (101 MHz, CDCl₃) δ 184.2, 158.1, 156.3, 140.8, 137.1, 129.5, 127.2, 122.6, 122.2, 121.1,

118.6, 109.4, 97.0, 56.2, 55.6, 50.0, 23.8, 15.9.

IR: 2931, 1614, 1512, 1581, 1469,1310, 1209, 869, 755, 677 cm⁻¹.

HRMS (FTMS+c ESI) m/z: [M + Na]⁺ calcd for C₁₈H₁₉NO₃Na⁺ 320.1257; found 320.1260.



	Retention Time	Area	% Area
1	4.441	7830543	50.19
2	9.345	7772395	49.81



	Retention Time	Area	% Area
1	4.343	23584971	99.16
2	9.705	198825	0.84

(S)-3-(5-ethyl-2,4-dimethoxyphenyl)-3-methylindolin-2-one (C5)



White soild; 28.9 mg, 93% yield, 99% ee; melting point: 132–135 °C; $[\alpha]_D^{14.9} = -66.2$ (*c* = 0.23 in CH₂Cl₂).

UPCC DAICEL CHIRALCEL AD-3, CO₂/MeOH = 90/10, flow rate = 1.5 mL/min, λ = 254 nm, t_R (major) = 5.07 min, t_R (minor) = 12.11 min.

¹**H NMR** (400 MHz, CDCl₃) δ 8.79 (s, 1H), 7.32 (s, 1H), 7.16 – 7.08 (m, 1H), 6.93 – 6.81 (m, 3H), 6.35 (s, 1H), 3.78 (s, 3H), 3.43 (s, 3H), 2.64 (dq, J = 7.5, 2.0 Hz, 2H), 1.72 (s, 3H), 1.23 (t, J = 7.5 Hz, 3H).

¹³**C NMR** (101 MHz, CDCl₃) δ 184.2, 158.1, 156.3, 140.8, 137.1, 129.5, 127.2, 122.6, 122.2, 121.1, 118.6, 109.4, 97.0, 56.2, 55.6, 50.0, 23.8, 15.9.

IR: 2965, 1615, 1504, 1308, 1207, 1136, 1107, 1034, 754, 676 cm⁻¹.

HRMS (FTMS+c ESI) m/z: [M + Na]⁺ calcd for C₁₉H₂₁NO₃Na⁺ 334.1414; found 334.1415.



	Retention Time	Area	% Area
1	5.167	3968763	50.79
2	11.659	3845984	49.21



	Retention Time	Area	% Area
1	5.069	27227599	99.05
2	12.105	261493	0.95

(S)-3-(5-isopropyl-2,4-dimethoxyphenyl)-3-methylindolin-2-one (C6)



White soild; 29.3 mg, 90% yield, 99% ee; melting point: 167–169 °C; $[\alpha]_D^{14.3} = -67.4$ (*c* = 0.29 in CH₂Cl₂).

UPCC DAICEL CHIRALCEL AD-3, CO₂/MeOH = 90/10, flow rate = 1.5 mL/min, λ = 254 nm, t_R (major) = 3.38 min, t_R (minor) = 9.05 min.

 $^{1}\text{H NMR} (400 \text{ MHz}, \text{CDCI}_{3}) \delta 8.79 \text{ (s, 1H)}, 7.37 \text{ (s, 1H)}, 7.16 - 7.08 \text{ (m, 1H)}, 6.93 - 6.79 \text{ (m, 3H)}, 6.93 - 6.79 \text{ (m, 3H)}, 6.93 - 6.79 \text{ (m, 3H)}, 7.16 - 7.08 \text{ (m, 1H)}, 7.16 - 7.08 \text{ (m, 2H)}, 7.16 - 7.16 \text{ ($

6.35 (s, 1H), 3.78 (s, 3H), 3.44 (s, 3H), 3.28 (m, 1H), 1.73 (s, 3H), 1.27 (dd, *J* = 6.9, 5.1 Hz, 6H).

¹³**C NMR** (101 MHz, CDCl₃) δ 184.3, 157.3, 155.9, 140.8, 137.0, 129.0, 127.2, 125.0, 122.6, 122.2, 121.2, 109.4, 97.1, 56.1, 55.7, 50.2, 26.9, 23.8, 23.1, 23.0.

IR: 2960, 1615, 1504, 1469, 1206, 1156, 1123, 1034, 750, 674 cm⁻¹.

HRMS (FTMS+c ESI) m/z: [M + Na]⁺ calcd for C₂₀H₂₃NO₃Na⁺ 348.1570; found 348.1573.



	Retention Time	Area	% Area
1	3.424	4994348	50.37
2	8.765	4920281	49.63



	Retention Time	Area	% Area
1	3.377	26726428	99.72
2	9.050	75418	0.28

(S)-3-(5-benzyl-2,4-dimethoxyphenyl)-3-methylindolin-2-one (C7)



Colorless oil; 34.7 mg, 93% yield, 99% ee; $[\alpha]_D^{14.6} = -65.4$ (c = 0.29 in CH₂Cl₂). **UPCC** DAICEL CHIRALCEL AS-3, CO₂/MeOH = 90/10, flow rate = 1.5 mL/min, $\lambda = 254$ nm, t_R (major) = 8.30 min, t_R (minor) = 13.84 min. ¹H NMR (400 MHz, CDCl₃) δ 8.90 (s, 1H), 7.34 – 7.15 (m, 5H), 7.13 – 7.07 (m, 1H), 6.92 – 6.83 (m,

1H), 6.82 - 6.76 (m,2H), 6.37 (s, 1H), 3.96 (m, 2H), 3.75 (s, 3H), 3.44 (s, 3H), 1.63 (s, 3H).

C7 ¹³**C NMR** (101 MHz, CDCl₃) δ 184.2, 157.9, 156.7, 141.5, 140.8, 136.9, 129.4, 128.9, 128.4, 127.2, 125.9, 122.5, 122.2, 121.5, 121.3, 109.4, 97.1, 56.1, 55.7, 50.0, 35.7, 23.7.

 $\textbf{IR}: 2929,\,1614,\,1505,\,1468,\,1207,\,1132,\,1104,\,1032,\,736,\,701,\,67~cm^{-1}.$

HRMS (FTMS+c ESI) m/z: [M + Na]⁺ calcd for C₂₄H₂₃NO₃Na⁺ 396.1570; found 396.1564.



	Retention Time	Area	% Area
1	8.196	8736500	50.29
2	13.058	8636538	49.71



	Retention Time	Area	% Area
1	8.299	12615482	99.44
2	13.839	70835	0.56

(S)-3-(6-methoxybenzo[d][1,3]dioxol-5-yl)-3-methylindolin-2-one (C8)



Colorless oil; 33.6 mg, 90% yield, 88% ee; $[\alpha]_{D}^{14.3} = -77.1$ (c = 0.28 in CH₂Cl₂). **UPCC** DAICEL CHIRALCEL AS-3, CO₂/MeOH = 90/10, flow rate = 1.5 mL/min, $\lambda = 254$ nm, t_R (major) = 5.76 min, t_R (minor) = 11.56 min. ¹H NMR (400 MHz, CDCl₃) δ 8.97 (s, 1H), 7.18 – 7.08 (m, 2H), 6.95 – 6.87 (m, 2H), 6.88 – 6.79 (m,

1H), 6.44 (s, 1H), 5.94 (m, 2H), 3.35 (s, 3H), 1.68 (s, 3H).

^{C8} ¹³C NMR (101 MHz, CDCl₃) δ 183.95, 152.5, 147.7, 141.8, 140.8, 136.7, 127.4, 122.4, 122.3, 109.5, 101.5, 96.7, 56.8, 50.3, 24.1

107.9, 101.5, 96.7, 56.8, 50.3, 24.1.

IR: 3209, 1618, 1504, 1278, 1195, 1165, 1117, 870, 756, 662 cm⁻¹.

HRMS (FTMS+c ESI) m/z: $[M + Na]^+$ calcd for $C_{17}H_{15}NO_4Na^+$ 320.0893; found 320.0895.



	Retention Time	Area	% Area
1	5.740	6547126	50.11
2	11.146	6519579	49.89



	Retention Time	Area	% Area
1	5.759	9498867	93.83
2	11.564	624503	6.17

(S)-3-methyl-3-(2,4,6-trimethoxyphenyl)indolin-2-one (C9)



White soild; 29.4 mg, 94% yield, 96% ee; melting point: 148–151 °C; $[\alpha]_D^{13.1} = -184.7$ (*c* = 0.18 in CH₂Cl₂).

UPCC DAICEL CHIRALCEL AS-3, CO₂/MeOH = 90/10, flow rate = 1.5 mL/min, λ = 254 nm, t_R (major) = 5.16 min, t_R (minor) = 13.68 min.

¹**H NMR** (400 MHz, CDCl₃) δ 8.28 (s, 1H), 7.16 – 7.06 (m, 2H), 6.94 – 6.83 (m, 2H), 6.14 (s, 2H), 3.77 (s, 3H), 3.69 (s, 6H), 1.88 (s, 3H).

¹³C NMR (101 MHz, CDCl₃) δ 185.0, 160.4, 140.1, 137.6, 127.1, 123.2, 122.2, 110.0, 109.1, 92.7, 56.0,

55.4, 50.9, 25.9.

IR: 2934, 1703, 1607, 1585, 1469, 1413, 1326, 1227, 1053, 814, 755 cm⁻¹.

HRMS (FTMS+c ESI) m/z: [M + Na]⁺ calcd for C₁₈H₁₉NO₄Na⁺ 336.1206; found 336.1206.



	Retention Time	Area	% Area
1	5.037	14506559	50.72
2	12.859	14093880	49.28



	Retention Time	Area	% Area
1	5.162	5508266	97.91
2	13.684	117820	2.09

(S)-3-(5-hydroxy-2,4-dimethoxyphenyl)-3-methylindolin-2-one (C10)



Colorless oil; 17.9 mg, 60% yield, 83% ee; $[\alpha] D^{12.7} = -50.3$ (c = 0.12 in CH₂Cl₂). **UPCC** DAICEL CHIRALCEL AD-3, CO₂/MeOH = 90/10, flow rate = 1.5 mL/min, λ = 254 nm, t_R (major) = 7.34 min, t_R (minor) = 10.51 min. ¹H NMR (400 MHz, CDCl₃) δ 8.50 (s, 1H), 7.25 - 7.14 (m, 1H), 7.09 - 6.89 (m, 3H), 6.64 - 6.59 (d, J

= 2.7 Hz, 1H), 6.49 – 6.43 (d, *J* = 2.8 Hz, 1H), 6.22 – 6.17 (m, 1H), 3.79 (s, 3H), 3.78 (s, 3H), 1.79 (s, 3H).

¹³**C NMR** (101 MHz, CDCl₃) *δ* 183.3, 153.1, 148.0, 140.6, 138.2, 135.4, 127.8, 126.1, 123.6, 122.6, 109.9, 104.5, 98.7, 56.2, 56.0, 51.3, 23.5.

IR: 2924, 2358, 1712, 1618, 1471, 1261, 1231, 1202, 1155, 1047 cm⁻¹.

HRMS (FTMS+c ESI) m/z: [M - H]⁻ calcd for C₁₇H₁₇NO₄Na⁺ 299.1085; found 299.1088.



0.00 0.50 1.00 1.50 2.00 2.50 3.00 3.50 4.00 4.50 5.00 5.50 6.00 6.50 7.00 7.50 8.00 8.50 9.00 9.50 10.00 10.50 11.00 11.50 12.00 12.50 13.00 13.50 14.00 14.50 15.00 Minutes

	Retention Time	Area	% Area
1	7.338	7775904	91.78
2	10.506	696338	8.22
(S)-3-(2,4-dimethoxy-6-methylphenyl)-3-methylindolin-2-one (C11)

(S)-3-(2,6-dimethoxy-4-methylphenyl)-3-methylindolin-2-one (C11')



White soild; 25.9 mg, 87% yield, 93% ee₁, 99% ee₂; melting point: 135–137 °C; $[\alpha]p^{12.7} = -121.0$ (*c* = 0.19 in CH₂Cl₂).

UPCC DAICEL CHIRALCEL AS-3, CO₂/MeOH = 90/10, flow rate = 1.5 mL/min, λ = 254 nm, t_R (major-major) = 5.16 min, t_R (major-minor) = 15.37 min, t_R (minor-major) = 4.41 min, t_R (minor-minor) = 12.12 min.

¹**H NMR** (400 MHz, CDCl₃) **(C11)** δ 8.85 (s, 1H), 7.17 – 7.10 (m, 1H), 7.06 – 6.98 (m, 1H), 6.95 – 6.88 (m, 2H), 6.36 – 6.27 (m, 2H), 3.76 (s, 6H), 3.54 (s, 3H), 1.89

(s, 3H).

¹³**C NMR** (101 MHz, CDCl₃) **(C11)** δ 185.5, 159.2, 140.1, 139.8, 137.4, 127.3, 123.2, 122.8, 122.3, 109.6, 107.1, 98.3, 55.8, 55.3, 55.3, 53.0, 27.3.

¹**H NMR** (400 MHz, CDCl₃) **(C11')** *δ* 8.77 (s, 1H), 7.09 – 7.06 (m, 2H), 6.87 – 6.83 (m, 2H), 6.39 (s, 2H), 3.69 (s, 6H), 2.29 (s, 3H), 1.90 (s, 3H).

¹³**C NMR** (101 MHz, CDCl₃) **(C11')** *δ* 185.4, 140.3, 138.9, 137.3, 127.1, 123.2, 122.8, 122.3, 114.5, 110.6, 109.3, 56.0, 51.1, 25.9, 21.8.

IR: 3197, 2925, 1712, 1606, 1579, 1468, 1320, 1234, 1154, 755 cm⁻¹.

HRMS (FTMS+c ESI) m/z: [M + Na]⁺ calcd for C₁₈H₁₉NO₃Na⁺ 320.1257; found 320.1259.



	Retention Time	Area	% Area
1	4.361	1708662	9.26
2	5.094	7551145	40.94
3	11.767	1682350	9.12
4	14.412	7502567	40.68



	Retention Time	Area	% Area
1	4.410	3162620	21.70
2	5.161	11008270	75.54
3	12.120	15685	0.11
4	15.372	386837	2.65

(R)-3-(3,4-dimethoxyphenyl)-3-methylindolin-2-one (C12)



Colorless oil; 22.4 mg, 79% yield, 77% ee; $[\alpha]_{D}^{18.6} = 118.6$ (c = 0.11 in CH₂Cl₂). UPCC DAICEL CHIRALCEL OX-3, CO₂/MeOH = 90/10, flow rate = 1.5 mL/min, $\lambda = 254$ nm, t_R (major) = 17.96 min, t_R (minor) = 10.47 min. ¹H NMR (400 MHz, CDCl₃) δ 8.51 (s, 1H), 7.29 – 7.20 (m, 1H), 7.19 – 7.12 (m, 1H), 7.12 – 7.02 (m, 1H), 7.00 – 6.94 (m, 1H), 6.89 – 6.76 (m, 3H), 3.84 (s, 3H), 3.81 (s, 3H), 1.80 (s, 3H).

 $^{13}\textbf{C}$ NMR (101 MHz, CDCl₃) δ 181.8, 148.7, 148.2, 140.1, 135.3, 132.8, 127.9, 124.3, 122.6, 118.8, 110.8, 110.0, 109.9, 55.7, 55.7, 52.0, 23.6.

IR: 3291, 2931, 2561, 1710, 1618, 1515, 1470, 1260, 1026, 751 cm⁻¹.

HRMS (FTMS+c ESI) m/z: [M + Na]⁺ calcd for C₁₇H₁₇NO₃Na⁺ 306.1101; found 306.1099.



	Retention Time	Area	% Area
1	10.453	19230932	49.96
2	18.644	19265111	50.04



	Retention Time	Area	% Area
1	10.472	5196158	11.52
2	17.957	39926279	88.48

(R)-3-(3,4-diethoxyphenyl)-3-methylindolin-2-one (C13)



White solid; 22.1 mg, 71% yield, 78% ee; melting point: 69–75 °C; $[\alpha]_D^{12.4} = 65.6$ (*c* = 0.43 in CH₂Cl₂).

UPCC DAICEL CHIRALCEL IB-3, CO₂/MeOH = 90/10, flow rate = 1.5 mL/min, λ = 254 nm, t_R (major) = 7.21 min, t_R (minor) = 5.50 min.

¹H NMR (400 MHz, CDCl₃) δ 8.66 (s, 1H), 7.26 – 7.20 (m, 1H), 7.16 – 7.13 (m, 1H), 7.08 – 7.03 (m, 1H), 6.98 – 6.94 (m, 1H), 6.87 – 6.77 (m, 3H), 4.08 – 3.98 (m, 5H), 1.78 (s, 3H), 1.44 – 1.35 (m, 7H).

¹³C NMR (101 MHz, CDCl₃) δ 182.0, 148.4, 148.0, 140.1, 135.4, 127.8, 124.2, 122.5, 119.0, 113.0, 112.6, 109.9, 64.5, 64.3, 52.0, 23.6, 14.6, 14.6.

IR: 3182, 2979, 1361, 1710, 1619, 1513, 1473, 1144, 1042, 751 cm⁻¹.

HRMS (FTMS+c ESI) m/z: $[M + H]^+$ calcd for $C_{19}H_{21}N_2ONa^+$ 312.1594; found 312.1595.



	Retention Time	Area	% Area
1	5.383	16605069	50.07
2	7.222	16559768	49.93



	Retention Time	Area	% Area
1	5.500	1322804	11.10
2	7.211	10593774	88.90

(S)-3-(2-methoxy-4-(methylthio)phenyl)-3-methylindolin-2-one (C14)



White solid; 20.3 mg, 68% yield, 50% ee; melting point: 115–120 °C; $[\alpha]_D^{19.1} = -23.0$ (*c* = 0.28 in CH₂Cl₂).

UPCC DAICEL CHIRALCEL OD-3, CO₂/MeOH = 90/10, flow rate = 1.5 mL/min, λ = 254 nm, t_R (major) = 9.95 min, t_R (minor) = 6.79 min.

¹**H NMR** (400 MHz, CDCl₃) δ 8.59 (s, 1H), 7.55 – 7.46 ((d, *J* = 8.1 Hz, 1H), 7.17 – 7.11 (m, 1H), 6.97 – 6.87 (m, 3H), 6.83 – 6.80 (m, 1H), 6.71 – 6.69 (m, 1H), 3.45 (s, 3H), 2.47 (s, 3H), 1.72 (s, 3H).

 $^{13}\textbf{C}$ NMR (101 MHz, CDCl_3) δ 183.1, 157.0, 140.4, 139.1, 136.0, 127.8, 127.1, 126.4, 122.2, 122.0,

118.5, 110.6, 109.1, 55.4, 49.9, 23.4, 15.8.

IR: 3214, 2360, 1709 1618, 1598, 1470, 1392, 1111, 1029, 769 cm⁻¹.

HRMS (FTMS+c ESI) m/z: $[M + Na]^+$ calcd for $C_{17}H_{17}N_2OSNa^+$ 322.0872; found 322.0872.



	Retention Time	Area	% Area
1	6.791	8028886	24.92
2	9.946	24194081	75.08



	Retention Time	Area	% Area
1	6.791	8028886	24.92
2	9.946	24194081	75.08

(S)-3-(furan-2-yl)-3-methylindolin-2-one (C15)



Colorless oil; 10.0 mg, 47% yield, 95% ee; $[\alpha]_D^{18.4} = 12.5$ (c = 0.11 in CH₂Cl₂). **UPCC** DAICEL CHIRALCEL IB-3, CO₂/MeOH = 95/5, flow rate = 1.5 mL/min, $\lambda = 254$ nm, t_R (major) = 3.59 min, t_R (minor) = 4.09 min. ¹H NMR (400 MHz, CDCl₃) δ 8.82 (s, 1H), 7.37 – 7.32 (m, 1H), 7.29 – 7.20 (m, 2H), 7.09 – 7.01 (m, 1H),

7.00 – 6.93 (m, 1H), 6.34 – 6.27 (m, 1H), 6.25 – 6.19 (m, 1H), 1.79 (s, 3H).

 $^{13}\textbf{C}$ NMR (101 MHz, CDCl_3) δ 179.6, 153.1, 142.7, 140.2, 133.0, 128.5, 124.0, 122.8, 110.2, 106.7, 49.5,

22.3.

IR: 3250, 2561, 1713, 1620, 1472, 1261, 1224, 1013, 751 cm⁻¹.

HRMS (FTMS+c ESI) m/z: $[M + Na]^+$ calcd for $C_{13}H_{11}NO_2Na^+$ 236.0682; found 236.0680.



	Retention Time	Area	% Area
1	3.629	2872568	50.02
2	4.128	2870055	49.98



	Retention Time	Area	% Area
1	3.588	12916335	74.84
2	4.093	4341181	25.16

(S)-3-methyl-3-(5-methylfuran-2-yl)indolin-2-one (C16)



White solid; 15.9 mg, 70% yield, 95% ee; melting point: 108–110 °C; $[\alpha]_D^{12.4} = 52.4$ (*c* = 0.21 in CH₂Cl₂). **UPCC** DAICEL CHIRALCEL OD-3, CO₂/MeOH = 90/10 flow rate = 1.5 mL/min, λ = 254 nm, t_R (major) = 3.39 min, t_R (minor) = 3.02 min.

¹**H NMR** (400 MHz, CDCl₃) δ 8.60 (s, 1H), 7.26 – 7.19 (m, 2H), 7.09 – 7.00 (m, 1H), 6.99 – 6.92 (d, J = 7.7 Hz, 1H), 6.12 – 6.06 (d, J = 3.1 Hz, 1H), 5.90 – 5.85 (m, 1H), 2.24 – 2.19 (m, 3H), 1.77 – 1.73 (m, 3H).

 $^{13}\textbf{C}$ NMR (101 MHz, CDCl_3) δ 179.9, 152.6, 151.3, 140.2, 133.5, 128.4, 124.2, 122.8, 110.2, 107.6, 106.3,

49.5, 22.4, 13.8.

IR: 3219, 2360, 1619, 1471, 1326, 1222, 1145, 1021, 752, 684 cm⁻¹.

HRMS (FTMS+c ESI) m/z: $[M + Na]^+$ calcd for $C_{14}H_{13}NO_2Na^+$ 250.0838; found 250.0836.



	Retention Time	Area	% Area
1	2.997	15224388	50.08
2	3.360	15177064	49.92



	Retention Time	Area	% Area
1	3.022	113504	2.47
2	3.385	4477880	97.53

(S)-3-(5-ethylfuran-2-yl)-3-methylindolin-2-one (C17)



Colorless oil; 17.4 mg, 72% yield, 95% ee; $[\alpha]_{D}^{18.0} = 42.4$ (c = 0.24 in CH₂Cl₂). **UPCC** DAICEL CHIRALCEL AS-3, CO₂/MeOH = 90/10 flow rate = 1.5 mL/min, $\lambda = 254$ nm, t_R (major) = 3.29 min, t_R (minor) = 4.08 min. ¹H NMR (400 MHz, CDCl₃) δ 8.30 (s, 1H), 7.25 – 7.20 (m, 2H), 7.08 – 7.00 (m, 1H), 6.96 – 6.91 (m, 1H), 6.10 – 6.04 (d, J = 3.1 Hz, 1H), 5.91 – 5.85 (m, 1H), 2.57 (q, J = 7.5 Hz, 1H), 1.75 (s, 3H), 1.16 (t, J = 7.5

Hz, 3H).

 $^{13}\textbf{C}$ NMR (101 MHz, CDCl₃) δ 179.6, 158.3, 151.1, 140.1, 133.5, 128.4, 124.2, 122.9, 110.1, 107.3, 104.6,

49.5, 22.5, 21.5, 12.0.

IR: 3217, 2361, 1715, 1472, 1261, 1191, 1015, 751 cm⁻¹.

HRMS (FTMS+c ESI) m/z: $[M + Na]^+$ calcd for $C_{15}H_{15}NO_2Na^+$ 264.0995; found 264.0993.



	Retention Time	Area	% Area
1	3.289	10012601	97.75
2	4.077	230082	2.25

(S)-3-(4,5-dimethylfuran-2-yl)-3-methylindolin-2-one (C18)



Colorless oil; 20.0 mg, 83% yield, 86% ee; $[\alpha]_{D}^{19.0} = -36.8$ (c = 0.38 in CH₂Cl₂). **UPCC** DAICEL CHIRALCEL ID-3, CO₂/MeOH = 95/5 flow rate = 1.5 mL/min, $\lambda = 254$ nm, t_R (major) = 4.80 min, t_R (minor) = 6.34 min. ¹H NMR (400 MHz, CDCl₃) δ 8.87 (s, 1H), 7.25 – 7.17 (m, 2H), 7.03 (m, 1H), 6.98 – 6.92 (m, 1H), 5.98 (s, 1H), 2.12 (s, 3H), 1.87 (s, 3H), 1.73 (s, 3H).

¹³**C NMR** (101 MHz, CDCl₃) δ 180.2, 150.0, 147.8, 140.3, 133.6, 128.4, 124.1, 122.8, 114.6, 110.3,

110.1, 49.5, 22.3, 11.6, 10.0.

IR: 2923, 2361, 1712, 1619, 1472, 1261, 1221, 751, 750 cm⁻¹.

HRMS (FTMS+c ESI) m/z: [M + Na]⁺ calcd for C₁₅H₁₅NO₂Na⁺ 264.0995; found 264.0992.



	Retention Time	Area	% Area
1	4.796	7180151	92.92
2	6.335	547454	7.08

(S)-3-(5-methoxyfuran-2-yl)-3-methylindolin-2-one (C19)



White solid; 14.4 mg, 59% yield, 77% ee; melting point: 119–121 °C; $[\alpha]_D^{18.2} = 32.5$ (c = 0.20 in CH₂Cl₂). **UPCC** DAICEL CHIRALCEL OD-3, CO₂/MeOH = 90/10 flow rate = 1.5 mL/min, $\lambda = 254$ nm, t_R (major) = 5.46 min, t_R (minor) = 3.67 min.

¹**H NMR** (400 MHz, CDCl₃) δ 8.51 (s, 1H), 7.24 – 7.18 (m, 2H), 7.08 – 7.01 (m, 1H), 6.97 – 6.89 (m, 1H), 6.12 – 6.07 (m, 1H), 5.08 – 5.01 (d, J = 3.3 Hz, 1H), 3.77 (s, 3H), 1.71 (s, 3H).

¹³**C NMR** (101 MHz, CDCl₃) δ 179.5, 161.6, 142.9, 140.2, 133.1, 128.5, 124.1, 122.9, 110.2, 108.1, 80.0, 57.7, 49.3, 22.0.

IR: 3250, 2361, 1713, 1616, 1582, 1472, 1261, 1047, 942, 751 cm⁻¹.

HRMS (FTMS+c ESI) m/z: [M + Na]⁺ calcd for C₁₄H₁₃NO₃Na⁺ 266.0788; found 266.0787.



	Retention Time	Area	% Area
1	3.639	1323787	50.07
2	5.488	1320042	49.93



	Retention Time	Area	% Area
1	3.667	2012735	11.32
2	5.457	15764838	88.68

(R)-3-(5-methoxythiophen-2-yl)-3-methylindolin-2-one (C20)



Colorless oil; 23.3 mg, 90% yield, 96% ee; $[\alpha]_{D}^{19.2} = 171.4$ (c = 0.41 in CH₂Cl₂). **UPCC** DAICEL CHIRALCEL IB-3, CO₂/MeOH = 90/10 flow rate = 1.5 mL/min, $\lambda = 254$ nm, t_R (major) = 9.56 min, t_R (minor) = 5.62 min. ¹H NMR (400 MHz, CDCl₃) δ 8.72 (s, 1H), 7.31 – 7.17 (m, 2H), 7.11 – 7.05 (m, 1H), 6.99 – 6.95 (m, 1H), 6.50 – 6.49 (d, J = 3.9 Hz, 1H), 6.02 – 5.98 (d, J = 3.9 Hz, 1H), 3.82 (s, 3H), 1.77 (s, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 180.7, 166.1, 140.3, 134.2, 130.2, 128.7, 124.5, 122.9, 122.5, 110.4, 103.5,

60.4, 50.6, 25.1.

IR: 3214, 2361, 1618, 1556, 1501, 1471, 1325, 1203, 1061, 752 cm⁻¹.

HRMS (FTMS+c ESI) m/z: [M + Na]⁺ calcd for C₁₄H₁₃NO₂SNa⁺ 282.0559; found 282.0558.



(S)-3-methyl-3-(1-octyl-1H-pyrrol-2-yl)indolin-2-one (C21)



White solid; 27.9 mg, 86% yield, 91% ee; melting point: 110–115 °C; $[\alpha]_D^{18.4} = 21.4$ (c = 0.31 in CH₂Cl₂). **UPCC** DAICEL CHIRALCEL AS-3, CO₂/MeOH = 90/10 flow rate = 1.5 mL/min, $\lambda = 254$ nm, t_R (major) = 9.56 min, t_R (minor) = 5.62 min.

¹**H NMR** (400 MHz, CDCl₃) δ 8.81 (s, 1H), 7.25 – 7.19 (m, 1H), 7.05 – 6.92 (m, 3H), 6.63 – 6.58 (m, 1H), 6.38 – 6.34 (m, 1H), 6.19 – 6.12 (m, 1H), 3.32 (m, 1H), 3.13 (m, 1H), 1.78 (s, 3H), 1.50 – 1.31 (m, 1H), 1.31 – 1.16 (m, 3H), 1.18 – 0.94 (m, 7H), 0.92 – 0.79 (m, 4H).

¹³**C NMR** (101 MHz, CDCl₃) δ 181.7, 139.6, 135.1, 129.9, 128.3, 124.0, 123.2, 122.4, 110.3, 109.0, 107.2, 49.0, 46.8, 31.8, 31.1, 29.2, 29.1, 26.9, 25.8, 22.7, 14.2.

IR: 3213, 2926, 2855, 2361, 1619, 1469, 1262, 1222, 751, 720 cm⁻¹.

HRMS (FTMS+c ESI) m/z: [M + Na]⁺ calcd for C₂₁H₂₈N₂ONa⁺ 347.2094; found 347.2098.



	Retention Time	Area	% Area
1	6.297	68487	4.74
2	11.183	1377000	95.26

(R)-3-(4-(dimethylamino)phenyl)-3-methylindolin-2-one (C22)



Colorless oil; 22.4 mg, 70% yield, 87% ee; $[\alpha]p^{20.1} = 31.4$ (c = 0.32 in CH₂Cl₂). **UPCC** DAICEL CHIRALCEL OJ-3, CO₂/MeOH = 90/10, flow rate = 1.5 mL/min, $\lambda = 254$ nm, t_R (major) = 3.27 min, t_R (minor) = 5.03 min. ¹H NMR (400 MHz, CDCl₃) δ 8.73 (s, 1H), 7.21 – 7.04 (m, 4H), 7.02 – 6.85 (m, 3H), 6.74 – 6.67 (m, 2H), 6.53 – 6.40 (m, 2H), 6.20 – 6.16 (m, 1H), 4.52 – 4.34 (m, 2H), 1.78 (s, 3H).

¹³**C NMR** (101 MHz, CDCl₃) δ 181.2, 139.6, 137.6, 134.5, 130.4, 128.4, 127.4, 127.0, 124.0, 123.9, 123.1,

110.4, 109.9, 107.5, 50.4, 49.0, 25.8.

IR: 3206, 1701, 1618, 1470, 1292, 1214, 1187, 1108, 755, 715 cm⁻¹.

HRMS (FTMS+c ESI) m/z: $[M + Na]^+$ calcd for $C_{20}H_{18}N_2ONa^+$ 325.1311; found 325.1308.



	Retention Time	Area	% Area
1	3.274	5197889	93.67
2	5.034	351243	6.33

(R)-3-(4-hydroxy-2-methylphenyl)-3-methylindolin-2-one (C23)



Colorless oil; 13.4 mg, 53% yield, 89% ee; $[\alpha]_{D}^{19.0} = 340.0$ (c = 0.12 in CH₂Cl₂). **UPCC** DAICEL CHIRALCEL ID-3, CO₂/MeOH = 90/10, flow rate = 1.5 mL/min, $\lambda = 254$ nm, t_R (major) = 6.49 min, t_R (minor) = 9.68 min. ¹H NMR (400 MHz, CDCl₃) δ 9.45 (s, 1H), 8.32 (s, 1H), 7.32 – 7.27 (m, 2H), 7.20 – 7.15 (m, 1H), 7.00 – 6.91 (m, 2H), 6.83 – 6.78 (m, 1H), 6.63 – 6.56 (m, 1H), 2.26 (s, 3H), 1.87 (s, 3H).

²³ ¹³C NMR (101 MHz, CDCl₃) δ 184.6, 156.1, 139.7, 139.5, 133.5, 128.4, 127.8, 125.8, 123.1, 122.2, 121.0, 10.6, 52.9, 22.6, 20.8

120.2, 110.6, 52.9, 22.6, 20.8.

IR: 3251, 2360, 1691, 1618, 1472, 1276, 1208, 750 cm⁻¹.

HRMS (FTMS+c ESI) m/z: $[M + Na]^+$ calcd for $C_{20}H_{22}N_2O_3Na^+$ 361.1523; found 361.1524.



	Retention Time	Area	% Area
1	6.488	4187461	94.31
2	9.679	252469	5.69

(R)-3-(2-ethyl-4-hydroxyphenyl)-3-methylindolin-2-one (C24)



Colorless oil; 8.3 mg, 31% yield, 79% ee; $[\alpha] p^{17.9} = 401.2$ (c = 0.10 in CH₂Cl₂). **UPCC** DAICEL CHIRALCEL IB-3, CO₂/MeOH = 90/10, flow rate = 1.5 mL/min, $\lambda = 254$ nm, t_R (major) = 8.02 min, t_R (minor) = 6.52 min. ¹H NMR (400 MHz, CDCl₃) δ 9.49 (s, 1H), 8.28 (s, 1H), 7.34 – 7.27 (m, 2H), 7.22 – 7.14 (m, 1H), 7.02 –

6.90 (m, 2H), 6.87 – 6.81 (m, 1H), 6.66 – 6.58 (m, 1H), 2.62 – 2.51 (m, 2H), 1.88 (s, 3H), 1.24 – 1.13 (m, 3H).

 $^{13}\textbf{C}$ NMR (101 MHz, CDCl₃) δ 184.5, 156.3, 150.7, 139.5, 133.4, 128.4, 127.8, 126.0, 123.1, 122.3,

118.3, 117.7, 110.6, 53.0, 33.5, 23.8, 22.5.

IR: 3251, 2966, 2360, 1691, 1618, 1472, 1332, 1209, 1131, 751 cm⁻¹.

HRMS (FTMS+c ESI) m/z: $[M + Na]^+$ calcd for $C_{17}H_{17}NO_2Na^+$ 290.1151; found 290.1151.



		Retention Time	Area	% Area
ſ	1	6.518	716350	10.53
	2	8.016	6086319	89.47

(R)-3-(4-hydroxy-2-isopropylphenyl)-3-methylindolin-2-one (C25)



Colorless oil; 6.7 mg, 24% yield, 76% ee; $[\alpha]_D^{18.2} = 272.1$ (c = 0.21 in CH₂Cl₂). **UPCC** DAICEL CHIRALCEL IB-3, CO₂/MeOH = 90/10, flow rate = 1.5 mL/min, $\lambda = 254$ nm, t_R (major) = 7.14 min, t_R (minor) = 5.86 min. ¹H NMR (400 MHz, CDCl₃) δ 9.55 (s, 1H), 8.22 (s, 1H), 7.33 – 7.27 (m, 2H), 7.21 – 7.16 (m, 1H), 7.01 - 6.93 (m, 2H), 6.89 – 6.86 (m, 1H), 6.67 – 6.62 (m, 1H), 2.87 – 2.77 (m, 1H), 1.89 (s, 3H), 1.22 –

1.18 (m, 6H).

 $^{13}\textbf{C}$ NMR (101 MHz, CDCl_3) δ 184.6, 156.4, 150.8, 139.6, 133.5, 128.5, 127.9, 126.1, 123.3, 118.5,

117.9, 110.7, 53.1, 33.6, 24.0, 23.8, 22.6.

IR: 3249, 2961, 2360, 1693, 1617, 1472, 1276, 751 cm⁻¹.

HRMS (FTMS+c ESI) m/z: $[M + Na]^+$ calcd for $C_{18}H_{19}NO_2Na^+$ 304.1308; found 304.1309.



	Retention Time	Area	% Area
1	5.858	786376	11.98
2	7.140	5778501	88.02

(R)-3-(4-hydroxy-3,5-dimethylphenyl)-3-methylindolin-2-one (C26)



Colorless oil; 19.0 mg, 71% yield, 70% ee; $[\alpha]_D^{19.3} = 55.8$ (c = 0.33 in CH₂Cl₂). **UPCC** DAICEL CHIRALCEL IB-3, CO₂/MeOH = 90/10, flow rate = 1.5 mL/min, $\lambda = 254$ nm, t_R (major) = 11.18 min, t_R (minor) = 9.72 min. ¹H NMR (400 MHz, CDCl₃) δ 8.91 (s, 1H), 7.24 - 7.18 (m, 1H), 7.11 - 7.07 (m, 1H), 7.06 - 7.00 (m,

1H), 6.98 – 6.93 (m, 1H), 6.86 (s, 2H), 2.15 (s, 6H), 1.76 (s, 3H).

¹³C NMR (101 MHz, CDCl₃) δ 182.9, 151.6, 140.3, 136.3, 131.8, 127.9, 126.8, 124.2, 123.3, 122.8,

110.2, 52.1, 23.3, 16.1.

IR: 3260, 2360, 1702, 1619, 1472, 1261, 1184, 750 cm⁻¹.

HRMS (FTMS+c ESI) m/z: [M + Na]⁺ calcd for C₁₇H₁₇NO₂Na⁺ 304.1308; found 304.1309.



	Retention Time	Area	% Area
1	9.720	894950	14.88
2	11.167	5119528	85.12

(R)-3-(4-(dimethylamino)phenyl)-3-methylindolin-2-one (C27)



White solid; 25.3 mg, 95% yield, 95% ee; melting point: 129–133 °C; $[\alpha]_D^{12.4} = 148.4$ (*c* = 0.63 in CH₂Cl₂).

UPCC DAICEL CHIRALCEL AS-3, CO₂/MeOH = 90/10, flow rate = 1.5 mL/min, λ = 254 nm, t_R (major) = 5.62 min, t_R (minor) = 8.25 min.

¹H NMR (400 MHz, CDCl₃) δ 8.42 (s, 1H), 7.26 – 7.10 (m, 4H), 7.08 – 7.00 (m, 1H), 6.97 – 6.91 (d, J = 7.8 Hz, 1H), 6.71 – 6.62 (m, 2H), 2.90 (s, 6H), 1.77 (s, 3H).

 $^{13}\textbf{C}$ NMR (101 MHz, CDCl₃) δ 182.5, 149.9, 140.5, 136.2, 128.3, 127.9, 127.5, 124.6, 122.7, 112.8,

110.0, 52.0, 40.7, 23.6.

IR: 3207, 1613, 1520, 1471, 1353, 1201, 948, 809, 751, 629 cm⁻¹.

HRMS (FTMS+c ESI) m/z: $[M + Na]^+$ calcd for C₁₇H₁₈N₂ONa⁺ 289.1311; found 289.1311. ¹H NMR (400 MHz, CDCl₃) δ 7.04 (t, J = 7.5 Hz, 1H), 6.94 (d, J = 7.8 Hz, 1H).



	Retention Time	Area	% Area
1	5.913	19243212	49.40
2	8.434	19709772	50.60



	Retention Time	Area	% Area
1	5.616	20220628	97.41
2	8.248	538014	2.59

(R)-3-(4-(diethylamino)phenyl)-3-methylindolin-2-one (C28)



White solid; 28.0 mg, 90% yield, 86% ee; melting point: 163–167 °C; $[\alpha]_D^{13.6} = 106.3$ (*c* = 0.27 in CH₂Cl₂).

UPCC DAICEL CHIRALCEL IB-3, CO₂/MeOH = 90/10, flow rate = 1.5 mL/min, λ = 254 nm, t_R (major) = 5.42 min, t_R (minor) = 7.76 min.

¹**H NMR** (400 MHz, CDCl₃) δ 8.97 (s, 1H), 7.24 – 7.16 (m, 1H), 7.18 – 7.09 (m, 3H), 7.09 – 6.96 (m, 1H), 6.98 – 6.91 (d, *J* = 7.7 Hz, 1H), 6.59 (d, *J* = 8.6 Hz, 2H), 3.30 (q, *J* = 7.1 Hz, 4H), 1.77 (s, 3H), 1.11 (t, *J* = 7.0 Hz, 6H).

¹³**C NMR** (101 MHz, CDCl₃) δ 183.1, 147.0, 140.7, 136.3, 127.8, 127.7, 126.9, 124.5, 122.6, 111.7, 110.2, 52.0, 44.4, 23.6, 12.7. ¹H NMR (400 MHz, CDCl₃)

IR: 3205, 2969, 1614, 1518, 1470, 1201, 1154, 809, 750, 676 cm⁻¹.

HRMS (FTMS+c ESI) m/z: $[M + Na]^+$ calcd for $C_{19}H_{22}N_2ONa^+$ 317.1624; found 317.1624.



	Retention Time	Area	% Area
1	5.371	17465684	49.93
2	7.378	17515441	50.07



	Retention Time	Area	% Area
1	5.422	32678876	92.85
2	7.757	2514753	7.15

(R)-3-(4-(dipropylamino)phenyl)-3-methylindolin-2-one (C29)



Colorless oil; 28.5 mg, 95% yield, 64% ee; $[\alpha]_D^{12.2} = 82.8$ (c = 0.24 in CH₂Cl₂). **UPCC** DAICEL CHIRALCEL AS-3, CO₂/MeOH = 90/10, flow rate = 1.5 mL/min, $\lambda = 254$ nm, t_R (major) = 3.91 min, t_R (minor) = 7.00 min.

¹H NMR (400 MHz, CDCl₃) δ 9.09 (s, 1H), 7.23 – 7.07 (m, 4H), 7.06 – 6.98 (m, 1H), 6.97 – 6.91 (d, J = 7.7 Hz, 1H), 6.59 – 6.50 (m, 2H), 3.18 (t, J = 7.4 Hz 4H), 1.76 (s, 3H), 1.56 (m, 4H), 0.88 (t, J = 7.4 Hz, 6H).

¹³**C NMR** (101 MHz, CDCl₃) *δ* 183.1, 147.3, 140.6, 136.2, 127.7, 127.5, 126.6, 124.4, 122.5, 111.6, 110.1, 52.9, 51.9, 23.4, 20.4, 11.5.

IR: 3205, 2960, 2872, 1615, 1516, 1200, 1154, 806, 745, 640 cm⁻¹.

HRMS (FTMS+c ESI) m/z: $[M + Na]^+$ calcd for $C_{21}H_{26}N_2ONa^+$ 345.1937; found 345.1940.



	Retention Time	Area	% Area
1	3.911	5833522	81.18
2	7.001	1352285	18.82

(R)-3-(4-(dimethylamino)-3-methylphenyl)-3-methylindolin-2-one (C30)



Colorless oil; 25.8 mg, 92% yield, 98% ee; $[\alpha]_D^{11.2} = 100.9$ (c = 0.25 in CH₂Cl₂). **UPCC** DAICEL CHIRALCEL AS-3, CO₂/MeOH = 90/10, flow rate = 1.5 mL/min, $\lambda = 254$ nm, t_R (major) = 3.78 min, t_R (minor) = 6.97 min. ¹H NMR (400 MHz, CDCl₃) δ 8.95 (s, 1H), 7.24 – 7.18 (m, 1H), 7.16 – 7.11 (m, 1H), 7.09 – 6.99 (m, 3H), 6.99 – 6.91 (m, 2H), 2.65 (s, 6H), 2.26 (s, 3H), 1.79 (s, 3H).

¹³**C NMR** (101 MHz, CDCl₃) *δ* 182.8, 152.0, 140.6, 136.1, 134.3, 132.2, 129.5, 128.0, 124.7, 124.5, 122.8, 118.5, 110.3, 52.3, 44.2, 23.5, 18.8.

IR: 3207, 2934, 2872, 1618, 1503, 1471, 1322, 817, 750, 640 cm⁻¹.

HRMS (FTMS+c ESI) m/z: $[M + Na]^+$ calcd for $C_{18}H_{20}N_2ONa^+$ 303.1468; found 303.1468.



	Retention Time	Area	% Area
1	3.777	5338215	99.13
2	6.967	46755	0.87

(R)-3-(4-(dimethylamino)-2-methylphenyl)-3-methylindolin-2-one (C31)



Colorless oil; 26.6 mg, 95% yield, 89% ee; $[\alpha]_{D}^{14.3} = -30.2$ (c = 0.36 in CH₂Cl₂). **UPCC** DAICEL CHIRALCEL IB-3, CO₂/MeOH = 90/10, flow rate = 1.5 mL/min, $\lambda = 254$ nm, t_R (major) = 12.39 min, t_R (minor) = 6.60 min. ¹H NMR (400 MHz, CDCl₃) δ 9.43 (s, 1H), 7.54 - 7.48 (d, J = 8.7 Hz, 1H), 7.19 - 7.11 (m, 1H), 6.97 -6.83 (m, 3H), 6.69 - 6.62 (m, 1H), 6.49 - 6.43 (m, 1H), 2.92 (s, 6H), 1.77 (s, 3H), 1.70 (s, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 183.9, 150.2, 140.3, 137.8, 136.7, 128.4, 127.6, 125.6, 123.2, 122.8, 116.1, 110.2, 110.0, 52.4, 40.6, 26.2, 20.00.

IR: 3209, 1610, 1509, 1470, 1409, 1371, 1219, 1182, 756, 613 cm⁻¹.

HRMS (FTMS+c ESI) m/z: [M + Na]⁺ calcd for C₁₈H₂₀N₂ONa⁺ 303.1468; found 303.1469.





	Retention Time	Area	% Area
1	6.601	1094884	5.74
2	12.394	17974983	94.26

(S)-3-(4-(dimethylamino)-2-methoxyphenyl)-3-methylindolin-2-one (C32)



White soild; 29.3 mg, 99% yield, 56% ee; melting point: 179–182 °C; $[\alpha]_D^{13.0} = -10.1$ (*c* = 0.42 in CH₂Cl₂).

UPCC DAICEL CHIRALCEL AS-3, CO₂/MeOH = 90/10, flow rate = 1.5 mL/min, λ = 254 nm, t_R (major) = 6.14 min, t_R (minor) = 13.11 min.

¹**H NMR** (400 MHz, CDCl₃) δ 8.93 (s, 1H), 7.45 – 7.38 (d, *J* = 8.6 Hz, 1H), 7.15 – 7.04 (m, 1H), 6.91 – 6.81 (m, 3H), 6.43 – 6.36 (dd, *J* = 8.6, 2.4 Hz, 1H), 6.19 – 6.14 (d, *J* = 2.4 Hz, 1H), 3.43 (s, 3H), 2.92 (s, 6H), 1.69 (s, 3H).

¹³**C NMR** (101 MHz, CDCl₃) δ 184.5, 157.9, 151.6, 140.7, 137.3, 128.0, 126.6, 122.4, 122.0, 117.8, 109.2, 105.0, 97.8, 55.5, 49.8, 40.7, 23.6.

IR: 2930, 1615, 1566, 1515, 1509, 1470, 1243, 1980, 815, 756 cm⁻¹.

HRMS (FTMS+c ESI) m/z: $[M + Na]^+$ calcd for $C_{18}H_{20}N_2O_2Na^+$ 319.1417; found 319.1420.



	Retention Time	Area	% Area
1	6.138	4803837	78.14
2	13.114	1343974	21.86

(S)-3-(2-chloro-4-(dimethylamino)phenyl)-3-methylindolin-2-one (C33)



Colorless oil; 24.9 mg, 83% yield, 88% ee; $[\alpha]_{D}^{13.8} = -41.4$ (*c* = 0.28 in CH₂Cl₂). **UPCC** DAICEL CHIRALCEL IB-3, CO₂/MeOH = 90/10, flow rate = 1.5 mL/min, λ = 254 nm, t_R (major) = 19.73 min, t_R (minor) = 13.18 min. ¹H NMR (400 MHz, CDCl₃) δ 9.00 (s, 1H), 7.52 (d, *J* = 8.8 Hz, 1H), 7.20 – 7.11 (m, 1H), 6.97 – 6.87 (m, 3H), 6.85 – 6.79 (m, 1H), 6.70 – 6.65 (m, 1H), 6.64 – 6.59 (m, 1H), 2.92 (s, 6H), 1.76 (s, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 183.1, 150.9, 140.9, 136.2, 134.8, 129.6, 127.6, 124.4, 122.6, 122.5, 114.4, 110.6, 110.1, 52.3, 40.4, 25.7.

IR: 3208, 2928, 1613, 1562, 1470, 1356, 1014, 797, 743, 683 cm⁻¹.

HRMS (FTMS+c ESI) m/z: $[M + Na]^+$ calcd for $C_{17}H_{17}^{34.9689}CIN_2ONa^+$ 323.0922; found 323.0923, $C_{17}H_{17}^{36.9659}CIN_2ONa^+$ 328.0892; found 328.0889.



	Retention Time	Area	% Area
1	13.152	7987638	49.71
2	19.843	8081636	50.29



	Retention Time	Area	% Area
1	13.175	490960	6.05
2	19.727	7627211	93.95

(S)-3-(2-bromo-4-(dimethylamino)phenyl)-3-methylindolin-2-one (C34)



Colorless oil; 34.5 mg, 94% yield, 88% ee; $[\alpha]_{D}^{14.1} = -31.6$ (c = 0.28 in CH₂Cl₂). **UPCC** DAICEL CHIRALCEL AS-3, CO₂/MeOH = 90/10, flow rate = 1.5 mL/min, $\lambda = 254$ nm, t_R (major) = 7.53 min, t_R (minor) = 17.10 min. ¹H NMR (400 MHz, CDCl₃) δ 8.75 (s, 1H), 7.56 – 7.49 (d, J = 8.8 Hz, 1H), 7.22 – 7.14 (m, 1H), 6.98 – 6.88 (m, 2H), 6.87 – 6.78 (m, 2H), 6.76 – 6.68 (dd, J = 8.8, 2.8 Hz, 1H), 2.93 (s, 6H), 1.77 (s, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 182.8, 150.9, 141.0, 136.3, 130.0, 127.7, 125.7, 124.9, 122.8, 122.6,

117.9, 111.1, 110.1, 53.7, 40.4, 26.4. IR: 3214, 2926, 1606, 1505, 1471, 1218, 1104, 959, 794, 755 cm⁻¹.

HRMS (FTMS+c ESI) m/z: $[M + Na]^+$ calcd for $C_{17}H_{17}^{78.9183}BrN_2ONa^+$ 367.0416; found 367.0419, $C_{17}H_{17}^{80.9163}BrN_2ONa^+$ 369.0369; found 369.0369.



	Retention Time	Area	% Area
1	7.529	17109431	93.80
2	17.096	1131196	6.20

(R)-3-(2-acetyl-4-(dimethylamino)phenyl)-3-methylindolin-2-one (C35)



Colorless oil; 22.2 mg, 72% yield, 94% ee; $[\alpha]_{D}^{11.3} = -32.1$ (c = 0.17 in CH₂Cl₂). **UPCC** DAICEL CHIRALCEL AS-3, CO₂/MeOH = 90/10, flow rate = 1.5 mL/min, $\lambda = 254$ nm, t_R (major) = 9.43 min, t_R (minor) = 7.52 min. ¹H NMR (400 MHz, CDCl₃) δ 7.85 (s, 1H), 7.62 (d, J = 8.8 Hz, 1H), 7.17 (m, 1H), 6.96 – 6.79 (m, 4H), 6.64 (d, J = 2.8 Hz, 1H), 2.97 (s, 6H), 1.99 (d, J = 4.3 Hz, 3H), 1.74 (s, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 204.0, 183.1, 149.3, 141.7, 141.1, 137.4, 129.9, 127.9, 124.2, 123.0,

122.1, 113.8, 111.3, 109.8, 51.2, 40.6, 29.1, 26.5.

IR: 2926, 1711, 1609, 1556, 1472, 1359, 1228, 1164, 806, 757 cm⁻¹.

HRMS (FTMS+c ESI) m/z: $[M + Na]^+$ calcd for $C_{19}H_{20}N_2O_2Na^+$ 331.1417; found 331.1417.



	Retention Time	Area	% Area
1	7.420	15070474	50.03
2	9.778	15054182	49.97



	Retention Time	Area	% Area
1	7.516	1348950	3.06
2	9.431	42753767	96.94

(R)-3-methyl-3-(4-(piperidin-1-yl)phenyl)indolin-2-one (C36)



Colorless oil; 30.0 mg, 98% yield, 94% ee; $[\alpha]_{D}^{10.8} = 87.5$ (c = 0.47 in CH₂Cl₂). **UPCC** DAICEL CHIRALCEL AS-3, CO₂/MeOH = 90/10, flow rate = 1.5 mL/min, $\lambda = 254$ nm, t_R (major) = 7.67 min, t_R (minor) = 10.98 min. ¹H NMR (400 MHz, CDCl₃) δ 9.05 (s, 1H), 7.24 – 7.09 (m, 4H), 7.06 – 6.98 (d, J = 7.4, 1H), 6.96 – 6.89 (d, J = 7.8 Hz, 1H), 6.89 – 6.80 (m, 2H), 3.10 (t, J = 5.4 Hz, 4H), 1.77 (s, 3H), 1.71 – 1.61 (m,

4H), 1.59 – 1.49 (m, 2H).

¹³C NMR (101 MHz, CDCl₃) δ 182.9, 151.3, 140.6, 136.1, 130.8, 127.9, 127.4, 124.4, 122.7, 116.4,

110.3, 52.2, 50.5, 25.9, 24.4, 23.6.

IR: 3206, 2932, 1616, 1514, 1471, 1384, 1219, 1120, 812, 744 cm⁻¹.

HRMS (FTMS+c ESI) m/z: [M + Na]⁺ calcd for C₂₀H₂₂N₂ONa⁺ 329.1624; found 329.1626. ¹H NMR (400 MHz, CDCl₃) δ 7.02 (td, *J* = 7.6, 1.1 Hz, 1H), 6.93 (d, *J* = 7.8 Hz, 1H), 3.10 (q, 4H).



	Retention Time	Area	% Area
1	7.671	16342218	97.15
2	10.980	479299	2.85

(R)-3-methyl-3-(4-morpholinophenyl)indolin-2-one (C37)



Colorless oil; 29.6 mg, 96% yield, 80% ee; $[\alpha]_{D}^{10.2} = 81.3$ (c = 0.67 in CH₂Cl₂). **UPCC** DAICEL CHIRALCEL AS-3, CO₂/MeOH = 90/10, flow rate = 1.5 mL/min, $\lambda = 254$ nm, t_R (major) = 12.58 min, t_R (minor) = 19.24 min. ¹**H NMR** (400 MHz, CDCl₃) δ 8.85 (s, 1H), 7.25 – 7.17 (m, 3H), 7.15 – 7.10 (m, 1H), 7.08 – 7.00 (m,

1H), 6.98 – 6.92 (m, 1H), 6.87 – 6.79 (m, 2H), 3.83 (t, *J* = 4.9 Hz, 4H), 3.11 (t, *J* = 4.9 Hz, 4H), 1.78 (s, 3H).

 $^{13}\textbf{C}$ NMR (101 MHz, CDCl₃) δ 182.6, 150.5, 140.6, 135.9, 131.8, 128.1, 127.6, 124.5, 122.8, 115.7,

110.2, 70.0, 52.1, 49.2, 23.6.

IR: 3202, 2924, 2853, 1708, 1616, 1514, 1326, 1119, 930, 814 cm⁻¹.

HRMS (FTMS+c ESI) m/z: $[M + Na]^+$ calcd for $C_{19}H_{20}N_2O_2Na^+$ 331.1417; found 331.1418.



	Retention Time	Area	% Area
1	12.581	9903336	89.86
2	19.244	1118053	10.14

(R)-3-methyl-3-(4-(methyl(phenyl)amino)phenyl)indolin-2-one (C38)



Colorless oil; 29.9 mg, 91% yield, 97% ee; $[\alpha]_{D}^{11.2} = 43.4$ (c = 0.32 in CH₂Cl₂). **UPCC** DAICEL CHIRALCEL IB-3, CO₂/MeOH = 90/10, flow rate = 1.5 mL/min, $\lambda = 254$ nm, t_R (major) = 19.64 min, t_R (minor) = 8.92 min. ¹H NMR (400 MHz, CDCl₃) δ 8.76 (s, 1H), 7.32 - 7.14 (m, 6H), 7.10 - 6.99 (m, 3H), 6.98 - 6.87 (m, 4H), 3.27 (s, 3H), 1.79 (3, 1H). ¹³C NMR (101 MHz, CDCl₃) δ 182.5, 148.8, 148.2, 140.5, 135.9, 132.7, 129.3, 128.1, 127.5, 124.5,

122.8, 121.9, 121.3, 119.7, 110.3, 52.3, 40.3, 23.6.

IR: 3209, 1615, 1511, 1471, 1344, 1218, 1211, 699 cm⁻¹.

HRMS (FTMS+c ESI) m/z: $[M + Na]^+$ calcd for $C_{22}H_{20}N_2ONa^+$ 351.1468; found 351.1470.



	Retention Time	Area	% Area
1	8.868	27373779	49.03
2	19.916	28459481	50.97



	Retention Time	Area	% Area
1	8.919	832949	2.77
2	19.638	29224671	97.23

(R)-3-(4-(benzyl(methyl)amino)phenyl)-3-methylindolin-2-one (C39)



Colorless oil; 33.9 mg, 99% yield, 94% ee; $[\alpha]_D^{10.2} = 90.2$ (c = 0.12 in CH₂Cl₂). **UPCC** DAICEL CHIRALCEL AS-3, CO₂/MeOH = 90/10, flow rate = 1.5 mL/min, $\lambda = 254$ nm, t_R (major) = 12.80 min, t_R (minor) = 21.84 min. ¹H NMR (400 MHz, CDCl₃) δ 8.83 (s, 1H), 7.32 – 7.17 (m, 6H), 7.15 – 7.11 (m, 3H), 7.06 – 6.97 (m, 1H), 6.96 – 6.90 (m, 1H), 6.70 – 6.62 (m, 2H), 4.47 (s, 2H), 2.98 (s, 3H), 1.76 (s, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 182.9, 149.0, 140.6, 139.1, 136.2, 128.7, 128.2, 127.9, 127.6, 127.0,

126.8, 124.5, 122.7, 112.4, 110.2, 56.7, 52.0, 38.7, 23.6.

IR: 2926, 1707, 1615, 1519, 1471, 1373, 1201, 1113, 808, 731 cm⁻¹.

HRMS (FTMS+c ESI) m/z: $[M + Na]^+$ calcd for $C_{23}H_{22}N_2ONa^+$ 365.1624; found 365.1627.



	Retention Time	Area	% Area
1	12.756	17097976	50.18
2	20.763	16977992	49.82



	Retention Time	Area	% Area
1	12.802	24786153	96.97
2	21.841	774766	3.03

ethyl (R)-N-methyl-N-(4-(3-methyl-2-oxoindolin-3-yl)phenyl)glycinate (C40)



Colorless oil; 33.5 mg, 99% yield, 93% ee; $[\alpha]_D^{12.8} = 88.1$ (c = 0.22 in CH₂Cl₂). **UPCC** DAICEL CHIRALCEL AS-3, CO₂/MeOH = 90/10, flow rate = 1.5 mL/min, $\lambda = 254$ nm, t_R (major) = 5.25 min, t_R (minor) = 8.95 min. ¹H NMR (400 MHz, CDCl₃) δ 8.92 (s, 1H), 7.24 – 7.08 (m, 4H), 7.06 – 6.98 (m, 1H), 6.97 – 6.90 (d, J

= 7.7 Hz, 1H), 6.64 – 6.56 (m, 2H), 4.15 (q, *J* = 7.1 Hz, 2H), 4.00 (s, 2H), 3.03 (s, 3H), 1.76 (s, 3H), 1.23 (t, *J* = 7.1 Hz, 2H).

¹³C NMR (101 MHz, CDCl₃) δ 182.9, 171.1, 148.1, 140.6, 136.1, 129.0, 127.9, 127.6, 124.5, 122.7, 112.4, 110.2, 61.0, 54.5, 52.0, 39.6, 23.6, 14.3.

 $IR: 2977, 1615, 1520, 1471, 1370, 1325, 1118, 948, 808, 640 \ cm^{-1}.$

HRMS (FTMS+c ESI) m/z: $[M + Na]^+$ calcd for $C_{20}H_{22}N_2O_3Na^+$ 361.1523; found 361.1524.



	Retention Time	Area	% Area
1	5.136	4741279	50.16
2	8.413	4710154	49.84



	Retention Time	Area	% Area
1	5.245	23275349	96.68
2	8.953	800447	3.32

(S)-3-(2,4-dimethoxyphenyl)-5-fluoro-3-methylindolin-2-one (C41)



Colorless oil; 26.2 mg, 87% yield, 94% ee; $[\alpha]_{D}^{11.4} = -137.5$ (c = 0.21 in CH₂Cl₂). **UPCC** DAICEL CHIRALCEL IB-3, CO₂/MeOH = 90/10, flow rate = 1.5 mL/min, λ = 254 nm, t_R (major) = 6.33 min, t_R (minor) = 4.21 min. ¹H NMR (400 MHz, CDCl₃) δ 8.96 (s, 1H), 7.51 – 7.41 (d, J = 8.6 Hz, 1H), 6.87 – 6.76 (m, 2H), 6.61 – 6.53 (m, 2H), 6.40 – 6.35 (d, J = 2.5 Hz, 1H), 3.80 (s, 3H), 3.45 (s, 3H), 1.71 (s, 3H).

¹³C NMR (101 MHz, CDCl₃) δ 184.0, 160.9(*J*_{C-F}= 282.5 Hz), 160.4, 158.0, 138.6(*J*_{C-F}= 7.8 Hz),

136.7, 128.3, 121.3, 113.6(J_{C-F} = 23.5 Hz), 110.6(J_{C-F} = 24.6 Hz), 109.9(J_{C-F} = 7.9 Hz), 104.7, 100.0, 55.5, 55.5, 50.7, 23.7. ¹⁹F NMR (376 MHz, CDCl₃) δ -121.4.

IR: 3218, 2931, 1611, 1505, 1486, 1306, 1263, 1031, 816, 778 cm⁻¹.

HRMS (FTMS+c ESI) m/z: $[M + Na]^+$ calcd for $C_{17}H_{16}FNO_3Na^+$ 324.1006; found 324.1008.



	Retention Time	Area	% Area
1	4.205	461392	3.04
2	6.328	14738106	96.96

(S)-5-chloro-3-(2,4-dimethoxyphenyl)-3-methylindolin-2-one (C42)



Colorless oil; 30.2 mg, 95% yield, 89% ee; $[\alpha]_D^{11.4} = 155.0$ (*c* = 0.51 in CH₂Cl₂). **UPCC** DAICEL CHIRALCEL IB-3, CO₂/MeOH = 90/10, flow rate = 1.5 mL/min, λ = 254 nm, t_R (major) = 8.79 min, t_R (minor) = 5.87 min. ¹**H NMR** (400 MHz, CDCl₃) δ 8.99 (s, 1H), 7.49 – 7.41 (d, *J* = 8.5 Hz, 1H), 7.13 – 7.05 (dd, *J* = 8.2,

2.2 Hz, 1H), 6.84 - 6.77 (m, 2H), 6.61 - 6.54 (dd, J = 8.5, 2.2 Hz, 1H), 6.40 - 6.35 (d, J = 2.5 Hz, 1H), 3.80 (s, 3H), 3.45 (s, 3H), 1.70 (s, 3H).

¹³**C NMR** (101 MHz, CDCl₃) δ 183.7, 160.9, 158.0, 139.4, 138.5, 128.3, 127.5, 127.3, 123.0, 121.1, 110.4, 104.7, 100.0, 55.5, 50.4, 23.7. ¹H NMR (400 MHz, CDCl₃)

IR: 3218, 2931, 1613, 1505, 1479, 1305, 1210, 1182, 818, 753 cm⁻¹.

HRMS (FTMS+c ESI) m/z: $[M + Na]^+$ calcd for $C_{17}H_{16}^{34.9689}CINO_3Na^+$ 340.0711; found 340.0714, $C_{17}H_{16}^{36.9659}CINO_3Na^+$ 342.0681; found 342.0681



	Retention Time	Area	% Area
1	5.851	18974606	49.89
2	8.924	19054497	50.11



(S)-5-bromo-3-(2,4-dimethoxyphenyl)-3-methylindolin-2-one (C43)



Colorless oil; 30.1 mg, 83% yield, 88% ee; $[\alpha]_D^{11.3} = 86.3$ (c = 0.18 in CH₂Cl₂). **UPCC** DAICEL CHIRALCEL AS-3, CO₂/MeOH = 90/10, flow rate = 1.5 mL/min, $\lambda = 254$ nm, t_R (major) = 10.64 min, t_R (minor) = 7.06 min.

¹**H NMR** (400 MHz, CDCl₃) δ 8.85 (s, 1H), 7.50 – 7.42 (d, *J* = 8.6 Hz, 1H), 7.28 – 7.22 (m, 1H),

6.95 – 6.90 (m, 1H), 6.81 – 6.74 (d, *J* = 2.0 Hz, 1H), 6.61 – 6.54 (dd, *J* = 8.6, 2.5 Hz, 1H), 6.40 – 6.35 (d, *J* = 2.5 Hz, 1H), 3.81 (s, 3H), 3.46 (s, 3H), 1.70 (s, 3H).

¹³**C NMR** (101 MHz, CDCl₃) δ 183.4, 160.9, 158.0, 139.8, 138.9, 130.1, 128.28, 125.8, 121.0, 114.8, 110.9, 104.6, 99.9, 55.5, 50.3, 23.7.

IR: 3206, 1613, 1586, 1505, 1475, 1306, 1210, 1143, 1031, 817 cm⁻¹.

HRMS (FTMS+c ESI) m/z: $[M + Na]^+$ calcd for $C_{17}H_{16}^{78.9183}BrNO_3Na^+$ 384.0206; found 384.0206, $C_{17}H_{16}^{80.9163}BrNO_3Na^+$ 386.0185; found 386.0184



	Retention Time	Area	% Area
1	6.908	19492357	49.04
2	10.397	20251708	50.96



	Retention Time	Area	% Area
1	7.062	650711	5.97
2	10.635	10244410	94.03

(S)-3-(2,4-dimethoxyphenyl)-5-iodo-3-methylindolin-2-one (C44)



Colorless oil; 34.4 mg, 84% yield, 86% ee; $[\alpha]_{D}^{13.3} = 137.0$ (c = 0.11 in CH₂Cl₂). **UPCC** DAICEL CHIRALCEL IB-3, CO₂/MeOH = 90/10, flow rate = 1.5 mL/min, $\lambda = 254$ nm, t_R (major) = 13.47min, t_R (minor) = 9.03 min. ¹H NMR (400 MHz, CDCl₃) δ 8.86 (s, 1H), 7.48 – 7.41 (m, 2H), 7.11 – 7.06 (m, 1H), 6.72 – 6.65 (d,

J = 8.5 Hz, 1H), 6.61 – 6.54 (dd, *J* = 8.5, 2.5 Hz, 1H), 6.40 – 6.35 (d, *J* = 2.5 Hz, 1H), 3.81 (s, 3H), 3.46 (s, 3H), 1.71 – 1.67 (s, 3H).

¹³**C NMR** (101 MHz, CDCl₃) δ 183.3, 160.9, 158.0, 140.5, 139.2, 136.1, 131.3, 128.3, 121.0, 111.5, 104.6, 99.9, 84.8, 55.6, 50.1, 23.7.

IR: 3236, 1611, 1586, 1472, 1305, 1210, 1143, 1131, 815, 643, 531 cm⁻¹.

HRMS (FTMS+c ESI) m/z: $[M + Na]^+$ calcd for $C_{17}H_{16}NIO_3Na^+$ 432.0067; found 432.0072.



	Retention Time	Area	% Area
1	9.031	3619821	7.02
2	13.468	47928385	92.98

(S)-3-(2,4-dimethoxyphenyl)-3,5-dimethylindolin-2-one (C45)



Colorless oil; 23.8 mg, 80% yield, 86% ee; $[\alpha]_D^{13.3} = -22.3$ (c = 0.17 in CH₂Cl₂). **UPCC** DAICEL CHIRALCEL IB-3, CO₂/MeOH = 90/10, flow rate = 1.5 mL/min, $\lambda = 254$ nm, t_R (major) = 7.04 min, t_R (minor) = 4.77 min. ¹H NMR (400 MHz, CDCl₃) δ 8.50 (s, 1H), 7.51 – 7.44 (d, J = 8.6 Hz, 1H), 6.96 – 6.89 (m, 1H), 6.78

(d, *J* = 7.8 Hz, 1H), 6.66 – 6.60 (m, 1H), 6.61 – 6.51 (dd, *J* = 8.6, 2.5 Hz, 1H), 6.40 – 6.35 (d, *J* = 2.5 Hz, 1H), 3.80 (s, 3H), 3.46 (s, 3H), 2.20 (s, 3H), 1.69 (s, 3H).

¹³**C NMR** (101 MHz, CDCl₃) δ 183.8, 160.6, 158.2, 138.3, 136.8, 131.6, 128.2, 127.6, 123.3, 122.2, 109.0, 104.6, 100.1, 55.7, 55.5, 50.1, 24.0, 21.2.

IR: 3236, 2930, 1611, 1586, 1504, 1210, 1143, 1031, 815, 643, 531 cm⁻¹.

HRMS (FTMS+c ESI) m/z: [M + Na]⁺ calcd for C₁₈H₁₉NO₃Na⁺ 320.1257, found 320.1257.



	Retention Time	Area	% Area
1	4.758	15286842	49.96
2	7.222	15309021	50.04



	Retention Time	Area	% Area
1	4.765	1999238	6.66
2	7.041	28004409	93.34

(S)-3-(2,4-dimethoxyphenyl)-5-methoxy-3-methylindolin-2-one (C46)



Colorless oil; 20.1 mg, 64% yield, 95% ee; $[\alpha]_D^{12.0} = 36.7(c = 0.41 \text{ in CH}_2\text{Cl}_2)$. **UPCC** DAICEL CHIRALCEL IB-3, CO₂/MeOH = 90/10, flow rate = 1.5 mL/min, λ = 254 nm, t_R (major) = 8.28 min, t_R (minor) = 5.64 min.

¹**H NMR** (400 MHz, CDCl₃) δ 8.44 (s, 1H), 7.50 – 7.42 (d, *J* = 8.6 Hz, 1H), 6.83 – 6.77 (m, 1H), 6.70 – 6.63 (m, 1H), 6.60 – 6.53 (m, 1H), 6.50 – 6.41 (dd, *J* = 8.6, 2.5 Hz, 1H), 6.40 – 6.34 (d, *J* = 2.5 Hz, 1H), 3.80 (s, 3H), 3.68 (s, 3H), 3.46 (s, 3H), 1.70 (s, 3H).

¹³**C NMR** (101 MHz, CDCl₃) *δ* 183.7, 160.7, 158.2, 155.7, 138.2, 134.2, 128.3, 121.9, 111.7, 109.8, 109.5, 104.6, 100.0, 55.8, 55.7, 55.5, 50.6, 24.0.

IR: 2932, 1609, 1489, 1306, 1265, 1207, 1143, 1030, 808, 736, 643 cm⁻¹.

HRMS (FTMS+c ESI) m/z: $[M + Na]^+$ calcd for $C_{18}H_{19}NO_4Na^+$ 336.1206, found 336.1206.



	Retention Time	Area	% Area
1	5.588	8543121	49.99
2	8.225	8546288	50.01



	Retention Time	Area	% Area
1	5.642	416410	2.61
2	8.283	15528559	97.39
(S)-3-benzyl-3-(4,5-dimethylfuran-2-yl)indolin-2-one (C47)



White solid; 19.0 mg, 60% yield, 71% ee; melting point: 123–126 °C; $[\alpha]_D^{18.9} = 28.8$ (c = 0.31 in CH₂Cl₂). **UPCC** DAICEL CHIRALCEL OD-3, CO₂/MeOH = 90/10 flow rate = 1.5 mL/min, $\lambda = 254$ nm, t_R (major) = 5.56 min, t_R (minor) = 3.90 min.

¹H NMR (400 MHz, CDCl₃) δ 7.90 (s, 1H), 7.24 – 7.13 (m, 2H), 7.11 – 6.99 (m, 4H), 6.92 – 6.84 (m, 2H), 6.73 – 6.66 (d, J = 7.7 Hz, 1H), 5.94 (s, 1H), 3.50 (m, 2H), 2.20 (s, 3H), 1.88 (s, 3H).

 $^{13}\textbf{C}$ NMR (101 MHz, CDCl₃) δ 177.9, 148.9, 148.0, 140.7, 135.3, 130.3, 128.5, 127.8, 126.8, 125.5,

122.4, 114.8, 110.8, 109.8, 55.3, 42.0, 11.7, 10.0.

IR: 3249, 2361, 1714, 1619, 1472, 1261, 1198, 1009, 751 cm⁻¹.

HRMS (FTMS+c ESI) m/z: $[M + Na]^+$ calcd for $C_{21}H_{19}NO_2Na^+$ 340.1308; found 340.1306.



	Retention Time	Area	% Area
1	3.902	2675620	49.60
2	5.666	2718407	50.40



	Retention Time	Area	% Area
1	3.896	3820873	14.66
2	5.559	22237187	85.34

(S)-3-(5-ethylfuran-2-yl)-5-fluoro-3-methylindolin-2-one (C48)



Colorless oil; 24.4 mg, 94% yield, 92% ee; $[\alpha]p^{12.4} = 17.4$ (c = 0.42 in CH₂Cl₂). **UPCC** DAICEL CHIRALCEL OXH, CO₂/MeOH = 90/10, flow rate = 1.0 mL/min, $\lambda = 254$ nm, t_R (major) = 11.63 min, t_R (minor) = 10.96 min. ¹H NMR (400 MHz, CDCl₃) δ 9.04 (s, 1H), 7.01 – 6.85 (m, 3H), 6.16 – 6.10 (d, J = 3.2 Hz, 1H), 5.93 –

5.87 (m, 1H), 2.57 (q, J = 7.6 Hz, 2H), 1.75 (s, 3H), 1.16 (t, J = 7.6 Hz, 3H). ¹³**C NMR** (101 MHz, CDCl₃) δ 180.1, 160.6, 158.5, 158.2, 150.4, 136.2, 135.1(d, J = 8.3 Hz), 135.1(d, J) = 8.3 Hz), 135.1(d, J)

J = 8.3 Hz), 114.9(d, J = 23.6 Hz), 114.7(d, J = 23.6 Hz), 112.2(d, J = 21.8 Hz), 112.0(d, J = 21.8 Hz),

110.9(d, J = 8.1 Hz), 110.9(d, J = 8.1 Hz), 107.5(d, J = 228.0 Hz), 104.7(d, J = 228.0 Hz), 50.1, 22.7, 21.5, 12.0.

 $^{19}\textbf{F}$ NMR (376 MHz, CDCl3) δ -120.28.

 $\textbf{IR}: 3231,\,1613,\,1520,\,1471,\,1353,\,1201,\,948,\,809,\,751,\,629~\text{cm}^{-1}.$

HRMS (FTMS+c ESI) m/z: $[M + Na]^+$ calcd for $C_{15}H_{14}FNO_2Na^+$ 282.0901 found 282.0901.



	Retention Time	Area	% Area	Height
1	10.989	2523980	49.92	146467
2	11.735	2532103	50.08	140971



	Retention Time	% Area	Height
1	10.962	4.21	90331
2	11.628	95.79	1810000

(S)-3-(5-ethylfuran-2-yl)-5-fluoro-3-methylindolin-2-one (C49)



Colorless oil; 26.2 mg, 95% yield, 95% ee; $[\alpha]_{D}^{19.0} = 104.4$ (c = 0.52 in CH₂Cl₂). **UPCC** DAICEL CHIRALCEL AS-3, CO₂/MeOH = 90/10, flow rate = 1.5 mL/min, $\lambda = 254$ nm, t_R (major) = 3.69 min, t_R (minor) = 6.27 min.

¹H NMR (400 MHz, CDCl₃) δ 9.20 (s, 1H), 7.22 – 7.16 (m, 2H), 6.94 – 6.87 (m, 1H), 6.19 – 6.10 (d, J = 3.2 Hz, 1H), 5.96 – 5.89 (m, 1H), 2.57 (q, J = 7.6 Hz, 1H), 1.74 (s, 3H), 1.16 (t, J = 7.6 Hz, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 179.9, 158.5, 150.3, 138.9, 135.2, 128.4, 128.2, 124.6, 111.4, 107.6,

104.7, 49.9, 22.3, 21.5, 11.9.

IR: 3228, 2975, 1619, 1479, 1187, 1015, 753, 557 cm⁻¹.

HRMS (FTMS+c ESI) m/z: $[M + Na]^+$ calcd for $C_{15}H_{14}^{34.9689}CINO_2Na^+$ 298.0606; found 298.0604, $C_{15}H_{14}^{36.9659}CINO_2Na^+$ 300.0576; found 300.0570



	Retention Time	Area	% Area
1	3.685	33750228	97.61
2	6.271	826780	2.39

(S)-4-bromo-3-(5-ethylfuran-2-yl)-3-methylindolin-2-one (C50)



Colorless oil; 22.1 mg, 49% yield, 93% ee; $[\alpha]_{D}^{18.3} = 178.5$ (c = 0.19 in CH₂Cl₂). **UPCC** DAICEL CHIRALCEL AS-3, CO₂/MeOH = 90/10, flow rate = 1.5 mL/min, $\lambda = 254$ nm, t_R (major) = 3.40 min, t_R (minor) = 5.55 min.

¹**H NMR** (400 MHz, CDCl₃) δ 8.74 (s, 1H), 7.18 – 7.06 (m, 2H), 6.94 – 6.87 (dd, *J* = 7.4, 1.3 Hz, 1H), 6.28 – 6.22 (d, *J* = 3.2 Hz, 1H), 5.97 – 5.91 (m, 1H), 2.53 (q, *J* = 7.6 Hz, 2H), 1.88 (s, 3H), 1.13 (t, *J* = 7.6 Hz, 3H).

 $^{13}\textbf{C}$ NMR (101 MHz, CDCl₃) δ 179.2, 158.1, 148.9, 142.3, 131.5, 129.9, 127.1, 119.7, 109.3, 109.1, 104.7,

51.3, 21.4, 18.9, 12.0.

IR: 3236, 2361, 1722, 1613, 1583, 1448, 1261, 1172, 751 cm⁻¹.

HRMS (FTMS+c ESI) m/z: $[M + Na]^+$ calcd for $C_{15}H_{14}^{78.9183}BrNO_2Na^+$ 342.0100; found 342.0100, $C_{15}H_{14}^{80.9163}BrNO_2Na^+$ 344.0008; found 344.0077



(S)-6-bromo-3-(5-ethylfuran-2-yl)-3-methylindolin-2-one (C51)



Colorless oil; 29.1 mg, 91% yield, 83% ee; $[\alpha]_D^{18.2} = 22.3$ (c = 0.38 in CH₂Cl₂). **UPCC** DAICEL CHIRALCEL AS-3, CO₂/MeOH = 90/10, flow rate = 1.5 mL/min, $\lambda = 254$ nm, t_R (major) = 4.20 min, t_R (minor) = 5.27 min.

¹**H NMR** (400 MHz, CDCl₃) δ 9.19 (s, 1H), 7.19 – 7.12 (m, 2H), 7.10 – 7.05 (m, 1H), 6.13 – 6.09 (d, J = 3.1 Hz, 1H), 5.93 – 5.87 (m, 1H), 2.56 (q, J = 7.6 Hz, 2H), 1.73 (s, 3H), 1.16 (t, J = 7.6 Hz, 3H).

¹³**C NMR** (101 MHz, CDCl₃) δ 180.1, 158.5, 150.3, 141.7, 132.4, 125.8, 125.4, 121.8, 113.8, 107.6, 104.7, 49.4, 22.2, 21.5, 12.0.

 $IR: 3235, 2975, 2361, 1720, 1610, 1480, 1451, 1276, 1015, 749 \text{ cm}^{-1}.$

HRMS (FTMS+c ESI) m/z: $[M + Na]^+$ calcd for $C_{15}H_{14}^{78.9183}BrNO_2Na^+$ 342.0100; found 342.0100, $C_{15}H_{14}^{80.9163}BrNO_2Na^+$ 344.0008; found 344.0079





	Retention Time	Area	% Area
1	4.197	18849949	91.49
2	5.272	1752571	8.51

(S)-3-(5-ethylfuran-2-yl)-5-iodo-3-methylindolin-2-one (C52)



Colorless oil; 32.5 mg, 92% yield, 91% ee; $[\alpha]_D^{19.9} = 56.8$ (c = 0.24 in CH₂Cl₂). **UPCC** DAICEL CHIRALCEL OXH, CO₂/MeOH = 90/10, flow rate = 1.0 mL/min, $\lambda = 254$ nm, t_R (major) = 6.36 min, t_R (minor) = 5.58 min.

¹**H NMR** (400 MHz, CDCl₃) δ 8.66 (s, 1H), 7.57 – 7.47 (m, 2H), 6.78 – 6.70 (d, J = 8.1 Hz, 1H), 6.15 – 6.10 (d, J = 3.2 Hz, 1H), 5.93 – 5.87 (m, 1H), 2.57 (q, J = 7.6 Hz, 2H), 1.73 (s, 3H), 1.17 (t, J = 7.6 Hz, 3H).

 $^{13}\textbf{C}$ NMR (101 MHz, CDCl₃) δ 179.1, 158.6, 150.3, 139.9, 137.3, 135.9, 133.0, 107.7, 104.7, 85.4, 49.6,

22.3, 21.5, 11.9.

IR: 3357, 2361, 1724, 1611, 1353, 1271, 948, 751 cm⁻¹.

HRMS (FTMS+c ESI) m/z: [M + Na]⁺ calcd for C₁₅H₁₄INO₂Na⁺ 389.9961; found 389.9962.



	Retention Time	Area	% Area
1	5.578	55613	4.59
2	6.359	1155068	95.41

(S)-3-(5-ethylfuran-2-yl)-3,5-dimethylindolin-2-one (C53)



Colorless oil; 21.4 mg, 84% yield, 95% ee; $[\alpha]_{D}^{21.7} = 73.3$ (*c* = 0.29 in CH₂Cl₂). **UPCC** DAICEL CHIRALCEL OXH, CO₂/MeOH = 90/10, flow rate = 1.0 mL/min, λ = 254 nm, t_R (major) $= 21.44 \text{ min}, t_R \text{ (minor)} = 17.96 \text{ min}.$

¹H NMR (400 MHz, CDCl₃) δ 8.69 (s, 1H), 7.05 – 6.97 (m, 2H), 6.87 – 6.78 (m, 1H), 6.10 – 6.03 (d, J = 3.2 Hz, 1H), 5.94 – 5.88 (m, 1H), 2.58 (q, J = 7.6 Hz, 2H), 2.31 (s, 3H), 1.74 (s, 3H), 1.16 (t, J = 7.6 Hz, 2H), 2.31 (s, 3H), 1.74 (s, 3H), 1.16 (t, J = 7.6 Hz, 2H), 2.31 (s, 3H), 3.11 (s, 3H), 3. 3H).

 $^{13}\textbf{C}$ NMR (101 MHz, CDCl_3) δ 180.0, 158.2, 151.3, 137.8, 133.6, 132.3, 128.7, 124.8, 109.9, 107.2, 104.6, 49.7, 22.4, 21.5, 21.3, 12.0.

IR: 3216, 2973, 1624, 1492, 1309, 1207, 956, 812, 812, 690 cm⁻¹.

HRMS (FTMS+c ESI) m/z: [M + Na]⁺ calcd for C₁₆H₁₇NO₂Na⁺ 278.1151; found 278.1152.



- 6 /
- 11/

	Retention Time	Area	% Area
1	17.961	1172705	2.59
2	21.441	44192170	97.41

(S)-3-benzyl-3-(2,4-dimethoxyphenyl)indolin-2-one (C54)



Yellow solid; 32.7 mg, 91% yield, 93% ee; melting point: 147–151 °C; $[\alpha]_D^{11.8} = -33.7$ (*c* = 0.12 in CH₂Cl₂).

UPCC DAICEL CHIRALCEL OD-3, CO₂/MeOH = 90/10, flow rate = 1.5 mL/min, λ = 254 nm, t_R (major) = 15.15 min, t_R (minor) = 20.78 min.

¹**H NMR** (400 MHz, CDCl₃) δ 7.69 (s, 1H), 7.62 – 7.54 (d, *J* = 8.7 Hz, 1H), 7.18 – 6.88 (m, 6H), 6.84

- 6.72 (m, 2H), 6.66 - 6.56 (m, 1H), 6.53 - 6.44 (m, 1H), 6.43 - 6.31 (d, J = 2.5 Hz, 1H), 3.80 (s,

3H), 3.52 (s, 2H), 3.41 (s, 3H).

¹³**C NMR** (101 MHz, CDCl₃) δ 181.2, 160.5, 158.3, 141.6, 135.0, 133.8, 130.4, 128.0, 127.5, 126.6, 123.2, 122.4, 121.9, 108.7, 104.8, 100.3, 55.7, 55.5, 55.4, 42.6.

IR: 2926, 1710, 1612, 1503, 1469, 1210, 1139, 1032, 780, 700 cm⁻¹.

HRMS (FTMS+c ESI) m/z: $[M + Na]^+$ calcd for $C_{23}H_{21}NO_3Na^+$ 382.1414; found 382.1416.



	Retention Time	Area	% Area
1	15.612	2927184	50.84
2	20.252	2830218	49.16



	Retention Time	Area	% Area
1	15.150	6272785	96.48
2	20.776	228838	3.52

(S)-3-(2,4-dimethoxyphenyl)-3-(3,4-dimethylbenzyl)indolin-2-one (C55)



White solid; 36.0 mg, 93% yield, 93% ee; melting point: 162–165 °C; $[\alpha]_D^{12.6} = -103.7$ (*c* = 0.62 in CH₂Cl₂).

UPCC DAICEL CHIRALCEL IB-3, CO₂/MeOH = 90/10, flow rate = 1.5 mL/min, λ = 254 nm, t_R (major) = 13.89 min, t_R (minor) = 6.46 min.

¹**H NMR** (400 MHz, CDCl₃) δ 7.63 – 7.55 (d, *J* = 8.6 Hz, 1H), 7.35 (s, 1H), 7.10 – 6.89 (m, 3H), 6.80 – 6.69 (m, 1H), 6.63 – 6.55 (m, 1H), 6.53 – 6.46 (m, 3H), 6.41 – 6.34 (d, *J* = 2.5 Hz, 1H), 3.80 (s, 3H), 3.45 (s, 2H), 3.42 (s, 3H), 2.11 (s, 3H), 2.01 (s, 3H).

¹³**C NMR** (101 MHz, CDCl₃) δ 180.9, 160.5, 158.2, 141.6, 135.4, 134.6, 134.2, 132.2, 131.6, 128.7, 128.1, 127.7, 127.3, 123.2, 122.5, 121.8, 108.6, 104.7, 100.3, 55.7, 55.5, 55.2, 42.2, 19.6, 19.5.

IR: 2925, 1612, 1585, 1489, 1209, 1162, 1083, 824, 751, 643 cm⁻¹.

HRMS (FTMS+c ESI) m/z: [M + Na]⁺ calcd for C₂₅H₂₅NO₃Na⁺ 410.1727; found 410.1729.



Minutes

	Retention Time	Area	% Area	Height
1	6.458	356538	3.49	24956
2	13.892	9845416	96.51	345723

(S)-3-(2,4-dimethoxyphenyl)-3-(4-(methylthio)benzyl)indolin-2-one (C56)



White solid; 38.1 mg, 94% yield, 92% ee; melting point: 137–139 °C; $[\alpha]_{D}^{12.5} = -142.2$ (*c* = 0.64 in CH₂Cl₂).

UPCC DAICEL CHIRALCEL IB-3, CO₂/MeOH = 90/10, flow rate = 1.5 mL/min, λ = 254 nm, t_R (major) = 23.20 min, t_R (minor) = 10.76 min.

¹H NMR (400 MHz, CDCl₃) δ 7.65 (s, 1H), 7.60 – 7.48 (d, *J* = 8.6 Hz, 1H), 7.10 – 7.00 (m, 1H),

C56 7.00 - 6.84 (m, 4H), 6.71 - 6.64 (m, 2H), 6.62 - 6.56 (dd, *J* = 8.6, 2.6 Hz, 1H), 6.52 - 6.45 (d, *J* = 7.7 Hz, 1H), 6.41 - 6.36 (d, *J* = 2.6 Hz, 1H), 3.80 (s, 3H), 3.46 (s, 2H), 3.41 (s, 3H), 2.37 (s, 3H).

¹³**C NMR** (101 MHz, CDCl₃) δ 181.0, 160.5, 158.2, 141.6, 136.3, 133.7, 131.8, 130.8, 128.0, 127.5, 125.6, 123.1, 122.3, 121.9, 108.9, 104.7, 100.2, 55.6, 55.5, 55.3, 42.0, 15.8.

IR: 3192, 2923, 1611, 1585, 1209, 1164, 1035, 830, 752, 642 cm⁻¹.

HRMS (FTMS+c ESI) m/z: [M + Na]⁺ calcd for C₂₄H₂₃NO₃SNa⁺ 404.1326; found 404.1329.



	Retention Time	Area	% Area
1	10.690	11752935	50.49
2	23.645	11523134	49.51



	Retention Time	Area	% Area
1	10.760	1046293	4.18
2	23.197	23971876	95.82

(S)-3-(2,4-dimethoxyphenyl)-3-(thiophen-2-ylmethyl)indolin-2-one (C57)



Yellow solid; 34.7 mg, 95% yield, 96% ee; melting point: 190–193 °C; $[\alpha]_D^{14.0} = -58.6$ (*c* = 0.42 in CH₂Cl₂).

UPCC DAICEL CHIRALCEL IB-3, CO₂/MeOH = 90/10, flow rate = 1.5 mL/min, λ = 254 nm, t_R (major) = 17.14 min, t_R (minor) = 8.48 min.

¹**H NMR** (400 MHz, CDCl₃) δ 7.88 (s, 1H), 7.58 – 7.44 (d, *J* = 8.6 Hz, 1H), 7.17 – 7.08 (m, 1H), 7.01

-6.88 (m, 3H), 6.80 - 6.71 (m, 1H), 6.68 - 6.61 (m, 1H), 6.61 - 6.55 (m, 2H), 6.43 - 6.36 (d, J = 2.5

Hz, 1H), 3.90 - 3.70 (m, 5H), 3.46 (s, 3H).

¹³**C NMR** (101 MHz, CDCl₃) *δ* 180.9, 160.5, 158.2, 142.0, 136.4, 133.6, 127.7, 127.6, 126.1, 124.6, 123.2, 122.1, 121.7, 108.8, 104.6, 100.2, 55.5, 55.4, 55.1, 36.8.

IR: 3203, 1612, 1585, 1470, 1306, 1210, 1034, 830, 752, 701 cm⁻¹.

HRMS (FTMS+c ESI) m/z: $[M + Na]^+$ calcd for $C_{21}H_{19}NO_3SNa^+$ 404.1326; found 404.1329.



	Retention Time	Area	% Area
1	8.475	1191058	1.80
2	17.138	65112504	98.20

(S)-3-(2,4-dimethoxyphenyl)-3-(thiophen-2-ylmethyl)indolin-2-one (C58)



White solid; 38.6 mg, 99% yield, 95% ee; melting point: 130–131 °C; $[\alpha]_D^{16.0} = -115.3$ (*c* = 0.62 in CH₂Cl₂).

UPCC DAICEL CHIRALCEL IB-3, CO₂/MeOH = 90/10, flow rate = 1.5 mL/min, λ = 254 nm, t_R (major) = 16.90 min, t_R (minor) = 7.88 min.

¹H NMR (400 MHz, CDCl₃) δ 7.63 – 7.55 (d, *J* = 8.7 Hz, 1H), 7.43 (s, 1H), 7.10 – 7.01 (m, 1H),

6.99 – 6.88 (m, 2H), 6.72 – 6.65 (m, 2H), 6.62 – 6.48 (m, 4H), 6.42 – 6.36 (d, *J* = 2.5 Hz, 1H),

3.80 (s, 3H), 3.69 (s, 3H), 3.47 (s, 2H), 3.42 (s, 3H).

¹³**C NMR** (101 MHz, CDCl₃) *δ* 181.0, 160.4, 158.2, 158.1, 141.4, 133.9, 131.2, 127.9, 127.3, 126.8, 123.1, 122.3, 121.8, 112.8, 108.6, 104.6, 100.1, 55.6, 55.4, 55.2, 55.0, 41.6.

IR: 3198, 2934, 1611, 1585, 1510, 1248, 1021, 964, 832, 752 cm⁻¹.

HRMS (FTMS+c ESI) m/z: $[M + Na]^+$ calcd for $C_{24}H_{26}NO_4Na^+$ 412.1519; found 412.1522.





	Retention Time	Area	% Area
1	7.884	613614	2.63
2	16.897	22712296	97.37

(S)-3-(2,4-dimethoxyphenyl)-3-(2-methylbenzyl)indolin-2-one (C59)



White solid; 36.6 mg, 98% yield, 98% ee; melting point: 167–170 °C; $[\alpha]_D^{16.0} = -68.1$ (*c* = 0.33 in CH₂Cl₂).

UPCC DAICEL CHIRALCEL IB-3, CO₂/MeOH = 90/10, flow rate = 1.5 mL/min, λ = 254 nm, t_R (major) = 14.77 min, t_R (minor) = 7.31 min.

¹**H NMR** (400 MHz, CDCl₃) δ 7.76 (s, 1H), 7.69 – 7.60 (d, *J* = 8.6 Hz, 1H), 7.12 – 7.01 (m, 1H), 7.03 – 6.86 (m, 4H), 6.83 – 6.74 (m, 1H), 6.65 – 6.51 (m, 3H), 6.42 – 6.37 (d, *J* = 2.5 Hz, 1H), 3.81 (s, 3H), 3.63 (m, 2H), 3.42 (s, 3H), 2.15 (s, 3H).

¹³**C NMR** (101 MHz, CDCl₃) *δ* 181.7, 160.4, 158.1, 141.7, 137.6, 133.9, 133.3, 130.6, 130.1, 127.9, 127.5, 126.6, 124.7, 123.6, 122.7, 121.7, 108.7, 104.7, 100.3, 55.8, 55.4, 55.0, 38.1, 20.0.

IR: 2924, 1613, 1585, 1505, 1469, 1267, 1210, 1139, 1035, 750 cm⁻¹.

HRMS (FTMS+c ESI) m/z: $[M - H]^{-}$ calcd for $C_{24}H_{23}NO_3Na^+$ 372.1605; found 372.1608.



	Retention Time	Area	% Area
1	7.152	17887939	49.78
2	15.035	18046042	50.22



	Retention Time	Area	% Area
1	7.309	688200	1.14
2	14.767	59558811	98.86

(S)-3-(2,4-dimethoxyphenyl)-3-(naphthalen-1-ylmethyl)indolin-2-one (C60)



White solid; 34.0 mg, 83% yield, 97% ee; melting point: 197–203 °C; $[\alpha]_D^{16.6} = -70.5$ (*c* = 0.18 in CH₂Cl₂).

UPCC DAICEL CHIRALCEL IB-3, CO₂/MeOH = 90/10, flow rate = 1.5 mL/min, λ = 254 nm, t_R (major) = 30.13 min, t_R (minor) = 15.13 min.

¹**H NMR** (400 MHz, CDCl₃) δ 8.11 – 8.02 (m, 1H), 7.78 – 7.66 (m, 2H), 7.65 – 7.55 (d, J = 8.2 Hz, 1H), 7.36 – 7.30 (m, 2H), 7.13 – 7.04 (m, 2H), 6.99 – 6.93 (m, 2H), 6.91 – 6.81 (m, 2H), 6.68 – 6.59 (dd, J = 8.2, 2.6 Hz, 1H), 6.46 – 6.41 (d, J = 2.6 Hz, 1H), 6.37 – 6.30 (m, 1H), 4.16 (d, J = 12.8 Hz,

1H), 3.96 (d, J = 12.8 Hz, 1H), 3.83 (s, 3H), 3.42 (s, 3H).

¹³**C NMR** (101 MHz, CDCl₃) δ 181.1, 160.6, 158.3, 141.5, 134.0, 133.5, 132.6, 131.3, 128.5, 128.2, 128.1, 127.5, 125.2, 125.2, 124.8, 124.6, 123.8, 122.7, 121.9, 108.5, 104.8, 100.5, 55.8, 55.6, 55.3, 37.6.

IR: 2927, 1612, 1505, 1470, 1417, 1209, 1139, 1035, 780, 752 cm⁻¹.

HRMS (FTMS+c ESI) m/z: [M - H]⁻ calcd for C₂₇H₂₃NO₃Na⁺ 432.1570; found 432.1573.



	Retention Time	Area	% Area
1	15.029	23454651	50.03
2	30.107	23428595	49.97



	Retention Time	Area	% Area
1	15.130	643419	1.87
2	30.131	33812932	98.13

(S)-3-allyl-3-(2,4-dimethoxyphenyl)indolin-2-one (C61)



Yellow solid; 20.1 mg, 65% yield, 94% ee; melting point: 151-153 °C; $[\alpha]_D^{16.0} = -62.3$ (c = 0.28 in CH₂Cl₂).

UPCC DAICEL CHIRALCEL IB-3, CO₂/MeOH = 90/10, flow rate = 1.5 mL/min, λ = 254 nm, t_R (major) = 7.03 min, t_R (minor) = 4.09 min.

¹**H NMR** (400 MHz, CDCl₃) δ 8.54 (s, 1H), 7.54 – 7.44 (d, J = 8.6 Hz, 1H), 7.17 – 7.08 (m, 1H), 6.93 –

C61 6.81 (m, 3H), 6.59 – 6.52 (dd, *J* = 8.6, 2.5 Hz, 1H), 6.40 – 6.34 (d, *J* = 2.5 Hz, 1H), 5.54 – 5.40 (m, 1H), 5.08 – 4.99 (m, 1H), 4.95 – 4.89 (m, 1H), 3.79 (s, 3H), 3.44 (s, 3H), 2.98 (d, *J* = 7.2 Hz, 2H).

¹³**C NMR** (101 MHz, CDCl₃) *δ* 181.9, 160.5, 158.4, 141.5, 134.4, 131.9, 128.2, 127.4, 122.9, 122.1, 121.9, 119.3, 1089.0, 104.7, 100.2, 55.7, 55.5, 54.0, 41.0.

IR: 3209, 1614, 1505, 1470, 1268, 1209, 1141, 1034, 925, 752 cm⁻¹.

HRMS (FTMS+c ESI) m/z: $[M - H]^{-}$ calcd for C₁₉H₁₉NO₃Na⁺ 332.1257; found 332.1259.



	Retention Time	Area	% Area
1	4.249	6379634	50.20
2	7.382	6329206	49.80



	Retention Time	Area	% Area
1	4.094	1034344	2.94
2	7.033	34153371	97.06

methyl (S)-2-(3-(2,4-dimethoxyphenyl)-2-oxoindolin-3-yl)acetate (C62)



White solid; 22.5 mg, 66% yield, 97% ee; melting point: 186–188 °C; $[\alpha]_D^{16.8} = -89.0$ (*c* = 0.25 in CH₂Cl₂).

UPCC DAICEL CHIRALCEL IB-3, CO₂/MeOH = 90/10, flow rate = 1.5 mL/min, λ = 254 nm, t_R (major) = 12.09 min, t_R (minor) = 6.04 min.

¹H NMR (400 MHz, CDCl₃) δ 8.38 (s, 1H), 7.32 – 7.28 (d, *J* = 8.7 Hz, 1H), 7.18 – 7.09 (m, 2H),

C62 6.95 - 6.83 (m, 2H), 6.51 - 6.46 (dd, *J* = 8.7, 2.5 Hz, 1H), 6.42 - 6.38 (d, *J* = 2.5 Hz, 1H), 3.77 (s, 3H), 3.59 - 3.55 (m, 4H), 3.48 (s, 3H), 3.28 (d, *J* = 15.1 Hz, 1H).

¹³**C NMR** (101 MHz, CDCl₃) *δ* 181.0, 170.3, 160.5, 158.5, 141.5, 133.1, 128.2, 127.9, 123.8, 122.1, 120.6, 109.2, 104.4, 100.2, 55.4, 52.4, 51.7, 40.2.

IR: 2928, 1716, 1613, 1506, 1470, 1263, 1210, 1031, 921, 753 cm⁻¹.

HRMS (FTMS+c ESI) m/z: $[M - H]^{-}$ calcd for C₁₉H₁₉NO₅Na⁺ 364.1155; found 364.1158.



	Retention Time	Area	% Area
1	6.019	3154376	50.07
2	12.406	3145448	49.93



	Retention Time	Area	% Area
1	6.036	135037	1.56
2	12.090	8519999	98.44

(S)-3-(2,4-dimethoxyphenyl)-3-isobutylindolin-2-one (C63)



White solid; 30.6 mg, 94% yield, 94% ee; melting point: 157–159 °C; $[\alpha]_D^{16.2} = -47.2$ (*c* = 0.44 in CH₂Cl₂).

UPCC DAICEL CHIRALCEL ID-3, CO₂/MeOH = 90/10, flow rate = 1.5 mL/min, λ = 254 nm, t_R (major) = 4.87 min, t_R (minor) = 6.58 min.

¹**H NMR** (400 MHz, CDCl₃) δ 9.09 (s, 1H), 7.54 – 7.47 (d, J = 8.6 Hz, 1H), 7.15 – 7.07 (m, 1H), 6.90 –

C63 6.80 (m, 3H), 6.59 – 6.51 (dd, *J* = 8.6, 2.6 Hz, 1H), 6.40 – 6.34 (d, *J* = 2.6 Hz, 1H), 3.78 (s, 3H), 3.42 (s, 3H), 2.32 – 2.14 (m, 2H), 1.53 – 1.41 (m, 1H), 0.92 (d, *J* = 6.7 Hz, 3H), 0.53 (d, *J* = 6.7 Hz, 3H).

¹³**C NMR** (101 MHz, CDCl₃) δ 183.3, 160.3, 158.2, 142.1, 135.1, 128.1, 127.3, 123.3, 123.1, 122.1, 109.0, 104.6, 100.2, 55.7, 55.5, 53.6, 45.4, 25.1, 24.7, 24.0.

IR: 3207, 2955, 1612, 1585, 1469, 1264, 1209, 1036, 752, 646 cm⁻¹.

HRMS (FTMS+c ESI) m/z: $[M - H]^{-}$ calcd for $C_{20}H_{23}NO_3Na^+$ 348.1570; found 348.1572.



	Retention Time	Area	% Area
1	4.856	11127062	96.89
2	6.584	357077	3.11

(S)-3-(2,4-dimethoxyphenyl)-3-phenylindolin-2-one (C64)

(S)-3-(2,6-dimethoxyphenyl)-3-phenylindolin-2-one (C64')



White soild; 30.4 mg, 88% yield, 84% ee₁, 99% ee₂; melting point: 101–105 °C; $[\alpha]_{D}^{15.3} = -221.0$ (*c* = 0.22 in CH₂Cl₂).

UPCC DAICEL CHIRALCEL OD-3, CO₂/MeOH = 90/10, flow rate = 1.5 mL/min, $\lambda = 254$ nm, t_R (major-major) = 9.61 min, t_R (major-minor) = 23.26 min, t_R (minor-major) = 14.36 min, t_R (minor-minor) = 30.48 min.

¹H NMR (400 MHz, CDCl₃) δ 8.96 – 8.44 (m, 1H), 7.52 – 7.39 (m, 2H), 7.34 – 7.25 (m, 3H), 7.23 – 7.17 (m, 1H), 7.05 – 6.96 (m, 2H), 6.92 – 6.87 (m, 1H), 6.84

- 6.76 (m, H), 6.45 - 6.34 (m, 2H), 3.76 (m, 3H), 3.51 (m, 3H). ¹³**C NMR** (101 MHz, CDCl₃) δ 181.6, 160.3, 158.3, 141.3, 138.9, 133.1, 131.0, 129.1, 128.12, 127.9, 127.6, 125.8, 124.3,

121.9, 109.6, 104.6, 100.0, 59.7, 55.7, 55.4.

IR: 3211, 1712, 1613, 1503, 1470, 1261, 1209, 1128, 1033, 700 cm⁻¹.

HRMS (FTMS+c ESI) m/z: $[M + Na]^+$ calcd for $C_{22}H_{19}NO_3Na^+$ 368.1257; found 368.1263.



	Retention Time	Area	% Area
1	9.607	8256329	84.46
2	14.362	720973	7.38
3	23.263	783595	8.02
4	30.476	14070	0.14

(S)-3-(4-chlorophenyl)-3-(2,4-dimethoxyphenyl)indolin-2-one (C65)



White soild; 36.8 mg, 97% yield, 93% ee; melting point: 180–183 °C; $[\alpha]_D^{14.8} = 200.0$ (*c* = 0.14 in CH₂Cl₂).

UPCC DAICEL CHIRALCEL ID-3, CO₂/MeOH = 90/10, flow rate = 1.5 mL/min, λ = 254 nm, t_R (major) = 7.07 min, t_R (minor) = 10.46 min.

¹H NMR (400 MHz, CDCl₃) δ 8.63 (s, 1H), 7.43 – 7.33 (m, 2H), 7.26 – 7.16 (m, 3H), 7.07 – 6.97

(m, 2H), 6.94 – 6.88 (m, 1H), 6.82 – 6.76 (m, 1H), 6.43 – 6.38 (m, 2H), 3.77 (s, 3H), 3.53 (s, 3H).

¹³**C NMR** (101 MHz, CDCl₃) δ 181.0, 160.6, 158.3, 141.3, 141.2, 134.2, 132.5, 130.8, 129.4, 129.2, 128.3, 127.9, 127.5, 125.9, 123.8, 122.4, 109.9, 104.7, 100.2, 59.6, 55.8, 55.5.

IR: 2929, 1712, 1613, 1504, 1471, 1263, 1209, 1131, 1035, 696 cm⁻¹.

HRMS (FTMS+c ESI) m/z: $[M + Na]^+$ calcd for $C_{22}H_{18}^{34.9689}CINO_3Na^+$ 402.0867; found 402.0871, $C_{22}H_{18}^{36.9659}CINO_3Na^+$ 404.0838; found 404.0839.



	Retention Time	Area	% Area
1	7.056	17425775	96.43
2	10.464	645252	3.57

(S)-3-(2,4-dimethoxyphenyl)-3-(p-tolyl)indolin-2-one (C66)



White soild; 28.0 mg, 78% yield, 81% ee; melting point: 225–231 °C; $[\alpha]_D^{14.6} = -113.9$ (*c* = 0.11 in CH₂Cl₂).

UPCC DAICEL CHIRALCEL ID-3, CO₂/MeOH = 90/10, flow rate = 1.5 mL/min, λ = 254 nm, t_R (major) = 6.79 min, t_R (minor) = 9.71 min.

 1 H NMR (400 MHz, CDCl₃) δ 8.47 (s, 1H), 7.34 – 7.28 (m, 1H), 7.23 – 7.15 (m, 3H), 7.13 – 7.07 (m, 1H), 7.23 – 7.15 (m, 2H), 7.13 – 7.07 (m, 2H)

1H), 7.03 – 6.95 (m, 2H), 6.92 – 6.88 (m, 1H), 6.85 – 6.75 (m, 1H), 6.43 – 6.34 (m, 2H), 3.76 (d, 3H),

3.45 (d, *J* = 46.4 Hz, 3H), 2.29 (s, 3H).

¹³**C NMR** (101 MHz, CDCl₃) δ 181.7, 160.1, 158.4, 141.3, 138.8, 137.9, 133.4, 131.2, 129.9, 128.5, 128.1, 127.9, 126.3, 125.9, 124.4, 122.0, 109.6, 104.7, 100.0, 59.7, 55.8, 55.5, 21.7.

IR: 2924, 1710, 1613, 1504, 1471, 1289, 1209, 1147, 1033, 785 cm⁻¹.

HRMS (FTMS+c ESI) m/z: $[M + Na]^+$ calcd for $C_{23}H_{21}NO_3Na^+$ 382.1414; found 382.1417.



	Retention Time	Area	% Area
1	6.792	4749792	90.41
2	9.713	503758	9.59

(3aS,8aS)-3a-(2,4-dimethoxyphenyl)-3,3a,8,8a-tetrahydro-2H-furo[2,3-b]indole (D1)



White soild; 34.5 mg, 87% yield, 97% ee; melting point: 97–100 °C; $[\alpha]_D^{18.8} = 124.7$ (*c* = 0.54 in CH₂Cl₂). **UPCC** DAICEL CHIRALCEL IB-3, CO₂/MeOH = 95/5, flow rate = 1.5 mL/min, λ = 254 nm, t_R (major) = 3.76 min, t_R (minor) = 4.36 min.

¹**H NMR** (400 MHz, CDCl₃) δ 7.18 – 7.07 (m, 2H), 7.05 – 6.98 (m, 1H), 6.71 – 6.63 (m, 1H), 6.49 – 6.45 (m, 1H), 6.43 – 6.36 (m, 2H), 5.59 (s, 1H), 4.11 – 4.05 (m, 1H), 3.77 (s, 1H), 3.73 (s, 3H), 3.59 – 3.51 (m, 1H), 2.96 (s, 3H), 2.89 – 2.80 (m, 1H), 2.35 – 2.30 (m, 1H).

¹³**C NMR** (101 MHz, CDCl₃) *δ* 160.0, 158.7, 151.4, 133.3, 128.7, 128.3, 124.8, 124.0, 117.3, 105.4, 103.9, 103.8, 99.9, 67.5, 58.8, 55.5, 39.7, 31.5.

IR: 2925, 1607, 1583, 1500, 1465, 1260, 1209, 1158, 953, 834 cm⁻¹.

HRMS (FTMS+c ESI) m/z: [M + Na]⁺ calcd for C₁₈H₁₉NO₃Na⁺ 334.1414; found 334.1416.



	Retention Time	Area	% Area
1	3.869	6746994	50.12
2	4.470	6714579	49.88



	Retention Time	Area	% Area
1	3.761	33846	1.49
2	4.359	2238599	98.51

(S)-3-(2,4-dihydroxyphenyl)-3-methylindolin-2-one (D2)



Yellow soild; 23.2 mg, 91% yield, 94% ee; melting point: 81–86 °C; $[\alpha]_D^{19.0} = 989.3$ (*c* = 0.23 in CH₂Cl₂). **UPCC** DAICEL CHIRALCEL ID-3, CO₂/MeOH = 90/10, flow rate = 1.5 mL/min, λ = 254 nm, t_R (major) = 12.0 min, t_R (minor) = 22.8 min.

¹**H NMR** (400 MHz, acetone-*d*₆) δ 9.64 (s, 1H), 7.22 – 7.15 (m, 1H), 7.14 – 7.06 (m, 2H), 7.04 – 6.93 (m, 2H), 6.36 – 6.28 (m, 2H), 1.69 (s, 3H).

¹³**C NMR** (101 MHz, acetone-*d*₆) δ 184.1, 158.8, 157.7, 142.2, 136.3, 129.2, 128.3, 124.7, 122.6, 118.9, 110.4, 107.1, 105.1, 51.7, 23.6.

IR: 3265 1680, 1617, 1521, 1470, 1377, 1204, 841, 755, 690 cm⁻¹.

HRMS (FTMS+c ESI) m/z: [M - H⁻] calcd for C₁₅H₁₂NO₃⁻ 254.0823; found 254.0825.



4.00 2.00 6.00 14.00 16.00 8.00 10.00 12.00 18.00 20.00 22.00 24.00 26.00 28.00 30.00 0.00 Minutes

	Retention Time	Area	% Area
1	11.994	20088333	96.97
2	22.755	627655	3.03

(R)-3-(3,4-dimethoxyphenyl)-3-methyl-1-pentylindolin-2-one (D3)



Colorless oil; 25.6 mg, 92% yield, 76% ee; $[\alpha]_D^{18.5}$ = 31.0 (*c* = 0.17 in CH₂Cl₂). **UPCC** DAICEL CHIRALCEL IB-3, CO₂/MeOH = 90/10, flow rate = 1.5 mL/min, λ = 254 nm, t_R (major) = 3.55 min, t_R (minor) = 3.01 min.

¹**H NMR** (400 MHz, CDCl₃) 7.33 – 7.28 (m, 1H), 7.22 – 7.16 (m, 1H), 7.10 – 7.05 (m, 1H), 6.95 – 6.90 (m, 1H), 6.88 – 6.84 (m, 1H), 6.83 – 6.74 (m, 2H), 3.83 (s, 3H), 3.81 (s, 3H), 3.79 – 3.62 (m, 2H), 1.75 (s, 3H), 1.73 – 1.65 (m, 2H), 1.43 – 1.27 (m, 4H), 0.90 – 0.82 (m, 3H).

¹³**C NMR** (101 MHz, CDCl₃) δ 179.6, 149.0, 148.4, 142.7, 135.2, 133.6, 128.1, 124.4, 122.6, 119.0, 111.1, 110.4, 108.7, 56.0, 56.0, 51.7, 40.2, 29.1, 27.2, 24.2, 22.5, 14.1.

IR: 2930, 2361, 1712, 1609, 1515, 1488, 1465, 1354, 1260, 1027 cm⁻¹.

HRMS (FTMS+c ESI) m/z: [M + Na⁺] calcd for $C_{22}H_{27}NO_3Na^+$ 376.1883; found 376.1883.



	Retention Time	Area	% Area
1	2.961	211608	49.66
2	3.509	214505	50.34



	Retention Time	Area	% Area
1	3.007	168930	11.31
2	3.552	1324385	88.69

(S)-3-(2,4-dihydroxyphenyl)-3-methylindolin-2-one (D4)



Colorless oil; 18.5 mg, 75% yield, 76% ee; $[\alpha]_D^{18.5} = 78.3$ (c = 0.11 in CH₂Cl₂). **UPCC** DAICEL CHIRALCEL OX-3, CO₂/MeOH = 90/10, flow rate = 1.5 mL/min, $\lambda = 254$ nm, t_R (major) = 5.10 min, t_R (minor) = 3.76 min.

¹H NMR (400 MHz, acetone-*d*₆) δ 7.28 – 7.19 (m, 1H), 7.12 – 7.02 (m, 2H), 6.84 – 6.75 (m, 1H), 6.75 – 6.72 (m, 2H), 5.96 – 5.93 (m, 2H), 3.84 – 3.65 (m, 2H), 1.73 – 1.64 (m, 5H), 1.39 – 1.26 (m, 4H), 0.90 – 0.82 (m, 3H).

¹³**C NMR** (101 MHz, acetone-*d*₆) δ 179.3, 148.7, 147.5, 143.5, 136.3, 136.0, 128.9, 124.9, 123.1, 120.6, 109.6, 108.5, 108.1, 102.0, 52.2, 40.3, 27.8, 24.0, 22.9, 14.2.

IR: 2927, 2361, 1711, 1609, 1488, 1466, 11354, 1354, 1103, 957 cm⁻¹.

HRMS (FTMS+c ESI) m/z: [M + Na⁺] calcd for $C_{21}H_{23}NO_3Na^+$ 360.1570; found 360.1568.





	Retention Time	Area	% Area
1	3.858	221098	12.10
2	5.097	1606579	87.90

12 Copies of NMR spectra for products















тт (ррш







f1 (ppm)






















































fl (ppm)

















10 0 -10 -20 -30 -40 -50 -60 -70 -80 -90 -100 -110 -120 -130 -140 -150 -160 -170 -180 -190 -200 -210 f1 (ppm)



210 200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0 -10 f1 (ppm)














20 10 0 -10 -20 -30 -40 -50 -60 -70 -80 -90 -100 -110 -120 -130 -140 -150 -160 -170 -180 -190 -200 -210 -2 f1 (ppm)











210 200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0 -10 f1 (ppm)













8.08
9.09
9.00
9.00
9.00
9.00
9.00
9.00
9.00
9.00
9.00
9.00
9.00
9.00
9.00
9.00
9.00
9.00
9.00
9.00
9.00
9.00
9.00
9.00
9.00
9.00
9.00
9.00
9.00
9.00
9.00
9.00
9.00
9.00
9.00
9.00
9.00
9.00
9.00
9.00
9.00
9.00
9.00
9.00
9.00
9.00
9.00
9.00
9.00
9.00
9.00
9.00
9.00
9.00
9.00
9.00
9.00
9.00
9.00
9.00
9.00
9.00
9.00
9.00
9.00
9.00
9.00
9.00
9.00
9.00
9.00
9.00
9.00
9.00
9.00
9.00
9.00
9.00
9.00
9.00
9.00
9.00
9.00
9.00
9.00
9.00
9.00
9.00
9.00
9.00
9.00
9.00
9.00
9.00
9.00
9.00
9.00
9.00
9.00
9.00
9.00
9.00
9.00
9.00
9.00
9.00
9.00
9.00
9.00
9.00
9.00
9.00
9.00
<li













B.8.3 B.6.3 B.









110 100 f1 (ppm)

 $\begin{array}{c} 1.72\\ 1.72\\ 1.72\\ 1.72\\ 1.72\\ 1.72\\ 1.73\\$ \cap 0---D3 ļ 9 9 4 2.0 2.9 3.0 2.7 7.5 7.4 7.3 7.1 f1 (ppm) 7.2 7.0 6.7 6.9 6.8 3.95 3.80 3.75 f1 (ppm) 3.90 3.85 3.65 3.70 Willia 2.9 3.0 1 2.1 2 5.5 77 10 77 4.1 g è 7.5 7.0 3.5 f1 (ppm) -0. 6.5 6.0 5.5 5.0 4.5 3.0 2.5 2.0 1.5 0.5 0.0 4.0 1.0 179.60 \lesssim ^{148.98} \sim ^{148.39} $\sim \frac{111.07}{110.37}$ ~ 108.74 ---- 40.19 ---- 14.09 $\sum_{-55.97}^{56.00}$ D3 56. 4 56. 2 56. 0 55. 8 55. 6 55. 4 55. 2 55. 0 f1 (ppm) 130 125 f1 (ppm) 150 145 140 135 120 115 110 105

90 fl (ppm) 180 50 30 170 160 150 140 130 120 70 60 40 20 10 0 110 100 80



13 Reference

1. (a)W. K. Yang, P. Dong, J. Xu, J. Yang, X. H. Liu, X. M. Feng, Chem. Eur. J., 2021, 27, 9272–9275; (b)J. Xu, R. Z. Li, N. Xu, X. H.

Liu, F. Wang, X. M. Feng, Org. Lett., 2021, 23, 1856-1861.

2. (a) Y. X. Wang, X. Huang, J. L. Huang, Y. Xiong, B. Qin, X. M. Feng, *Synlett*, 2005, 2445–2448; (b) X. H. Liu, L. Lin, X. M. Feng, *Acc. Chem. Res.*, **2011**, *44*, 574–587; (c) X. H. Liu, L. Lin, X. M. Feng, *Org. Chem. Front.*, **2014**, *1*, 298–302; (d) Y. S. Chen, Y. Liu, Z. J. Li, S. X. Dong, X. H. Liu, X. M. Feng, *Angew. Chem., Int. Ed.*, **2018**, *57*, 16554–16558.

3. (a) G. M. Sheldrick, Acta Cryst., 2008, 64, 112–122. (b) G. M. Sheldrick, Acta Cryst., 2015, 71, 3–8. (c) G. M. Sheldrick, Acta Cryst., 2015, 71, 3–8. (d) O.V. Dolomanov, Bourhis, L.J., Gildea, R.J., Howard, J. A. K., Puschmann, H. J. Appl. Cryst., 2009, 42, 339–341.

4. A. L. Spek, J. Appl. Cryst., 2003, 36, 7-13.